MXPA03005612A - Compuestos de pirazol utiles como inhibidores de la proteina cinasa. - Google Patents

Compuestos de pirazol utiles como inhibidores de la proteina cinasa.

Info

Publication number: MXPA03005612A
Authority: MX; Mexico
Prior art keywords: protein kinase; kinase inhibitors; compounds useful; pyrazole compounds; pyrazole
Prior art date: 2000-12-21

Application number

MXPA03005612A

Other languages

English (en)

Inventor

Bebbington David

Original Assignee

Vertex Pharma

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2000-12-21

Filing date

2001-12-20

Publication date

2003-10-06

2001-12-20 Application filed by Vertex Pharma filed Critical Vertex Pharma

2003-10-06 Publication of MXPA03005612A publication Critical patent/MXPA03005612A/es

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
- A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
- C07D407/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
- C07D473/16—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two nitrogen atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
- C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
- C07D493/04—Ortho-condensed systems
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Public Health (AREA)
Engineering & Computer Science (AREA)
General Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Veterinary Medicine (AREA)
Pharmacology & Pharmacy (AREA)
Chemical Kinetics & Catalysis (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Neurology (AREA)
Biomedical Technology (AREA)
Neurosurgery (AREA)
Physical Education & Sports Medicine (AREA)
Diabetes (AREA)
Immunology (AREA)
Virology (AREA)
Orthopedic Medicine & Surgery (AREA)
Oncology (AREA)
Endocrinology (AREA)
Rheumatology (AREA)
Cardiology (AREA)
Communicable Diseases (AREA)
Heart & Thoracic Surgery (AREA)
Hematology (AREA)
Psychiatry (AREA)
Obesity (AREA)
Pulmonology (AREA)
Molecular Biology (AREA)
Pain & Pain Management (AREA)
Emergency Medicine (AREA)
Psychology (AREA)
Hospice & Palliative Care (AREA)
Biotechnology (AREA)
Urology & Nephrology (AREA)

MXPA03005612A 2000-12-21 2001-12-20 Compuestos de pirazol utiles como inhibidores de la proteina cinasa. MXPA03005612A (es)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US25788700P	2000-12-21	2000-12-21
US28694901P	2001-04-27	2001-04-27
PCT/US2001/049594 WO2002059112A2 (en)	2000-12-21	2001-12-20	Pyrazole compounds useful as protein kinase inhibitors

Publications (1)

Publication Number	Publication Date
MXPA03005612A true MXPA03005612A (es)	2003-10-06

Family

ID=26946273

Family Applications (8)

Application Number	Title	Priority Date	Filing Date
MXPA03005610A MXPA03005610A (es)	2000-12-21	2001-12-19	Compuestos de pirazol utiles como inhibidores de la proteina cinasa.
MXPA03005608A MXPA03005608A (es)	2000-12-21	2001-12-19	Compuestos de pirazol utiles como inhibidores de la proteina cinasa.
MXPA03005609A MXPA03005609A (es)	2000-12-21	2001-12-19	Compuestos de pirazol utiles como inhibidores de la proteina cinasa.
MXPA03005605A MXPA03005605A (es)	2000-12-21	2001-12-19	Compuestos de pirazol utiles como inhibidores de la proteina cinasa.
MXPA03005607A MXPA03005607A (es)	2000-12-21	2001-12-19	Compuestos de pirazol utiles como inhibidores de la proteina cinasa.
MXPA03005606A MXPA03005606A (es)	2000-12-21	2001-12-19	Compuestos de pirazol utiles como inhibidores de la proteina cinasa.
MXPA03005611A MXPA03005611A (es)	2000-12-21	2001-12-20	Compuestos de pirazol utiles como inhibidores de la proteina cinasa.
MXPA03005612A MXPA03005612A (es)	2000-12-21	2001-12-20	Compuestos de pirazol utiles como inhibidores de la proteina cinasa.

Family Applications Before (7)

Application Number	Title	Priority Date	Filing Date
MXPA03005610A MXPA03005610A (es)	2000-12-21	2001-12-19	Compuestos de pirazol utiles como inhibidores de la proteina cinasa.
MXPA03005608A MXPA03005608A (es)	2000-12-21	2001-12-19	Compuestos de pirazol utiles como inhibidores de la proteina cinasa.
MXPA03005609A MXPA03005609A (es)	2000-12-21	2001-12-19	Compuestos de pirazol utiles como inhibidores de la proteina cinasa.
MXPA03005605A MXPA03005605A (es)	2000-12-21	2001-12-19	Compuestos de pirazol utiles como inhibidores de la proteina cinasa.
MXPA03005607A MXPA03005607A (es)	2000-12-21	2001-12-19	Compuestos de pirazol utiles como inhibidores de la proteina cinasa.
MXPA03005606A MXPA03005606A (es)	2000-12-21	2001-12-19	Compuestos de pirazol utiles como inhibidores de la proteina cinasa.
MXPA03005611A MXPA03005611A (es)	2000-12-21	2001-12-20	Compuestos de pirazol utiles como inhibidores de la proteina cinasa.

Country Status (27)

Country	Link
US (16)	US6989385B2 (es)
EP (10)	EP1702920B1 (es)
JP (19)	JP4234435B2 (es)
KR (8)	KR100889246B1 (es)
CN (6)	CN1486310A (es)
AP (2)	AP1588A (es)
AR (4)	AR040925A1 (es)
AT (9)	ATE327989T1 (es)
AU (7)	AU2001297619B2 (es)
BR (2)	BR0116493A (es)
CA (8)	CA2432131C (es)
CY (1)	CY1106297T1 (es)
DE (8)	DE60119776T2 (es)
DK (3)	DK1353916T3 (es)
ES (7)	ES2272567T3 (es)
HU (5)	HUP0400908A3 (es)
IL (8)	IL156368A0 (es)
MX (8)	MXPA03005610A (es)
MY (1)	MY140377A (es)
NO (5)	NO20032671L (es)
NZ (8)	NZ526472A (es)
PL (2)	PL210066B1 (es)
PT (3)	PT1345922E (es)
RU (1)	RU2355688C2 (es)
SI (2)	SI1353916T1 (es)
TW (2)	TWI290551B (es)
WO (8)	WO2002050065A2 (es)

Families Citing this family (376)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6982260B1 (en)	1999-11-22	2006-01-03	Warner-Lambert Company	Quinazolines and their use for inhibiting cyclin-dependent kinase enzymes
US6660731B2 (en) *	2000-09-15	2003-12-09	Vertex Pharmaceuticals Incorporated	Pyrazole compounds useful as protein kinase inhibitors
WO2002022608A1 (en)	2000-09-15	2002-03-21	Vertex Pharmaceuticals Incorporated	Pyrazole compounds useful as protein kinase inhibitors
US7473691B2 (en) *	2000-09-15	2009-01-06	Vertex Pharmaceuticals Incorporated	Pyrazole compounds useful as protein kinase inhibitors
DE60135676D1 (de) *	2000-12-05	2008-10-16	Vertex Pharma	Inhibitoren von c-jun n-terminalen kinasen (jnk) und anderen proteinkinasen
ATE327989T1 (de) *	2000-12-21	2006-06-15	Vertex Pharma	Pyrazolverbindungen als protein-kinase- inhibitoren
MXPA03008658A (es) *	2001-03-23	2005-04-11	Bayer Ag	Inhibidores de rho-cinasa.
ATE400274T1 (de)	2001-04-10	2008-07-15	Merck & Co Inc	Hemmstoffe der akt aktivität
US7105667B2 (en) *	2001-05-01	2006-09-12	Bristol-Myers Squibb Co.	Fused heterocyclic compounds and use thereof
US7138404B2 (en) *	2001-05-23	2006-11-21	Hoffmann-La Roche Inc.	4-aminopyrimidine derivatives
US7115617B2 (en)	2001-08-22	2006-10-03	Amgen Inc.	Amino-substituted pyrimidinyl derivatives and methods of use
US6939874B2 (en)	2001-08-22	2005-09-06	Amgen Inc.	Substituted pyrimidinyl derivatives and methods of use
CZ2004359A3 (cs) *	2001-09-26	2004-09-15	Pharmacia Italia S.P.A.	Aminoindazolové deriváty aktivní jako inhibitory kinázy, způsob jejich přípravy a farmaceutické prostředky obsahující tyto deriváty
WO2003026666A1 (en) *	2001-09-26	2003-04-03	Bayer Pharmaceuticals Corporation	2-phenylamino-4- (5-pyrazolylamino)-pyrimidine derivatives as kinase inhibitors, in particular, as src kinase inhibitors
SE0104140D0 (sv)	2001-12-07	2001-12-07	Astrazeneca Ab	Novel Compounds
US20030187026A1 (en)	2001-12-13	2003-10-02	Qun Li	Kinase inhibitors
AU2002361846A1 (en) *	2001-12-21	2003-07-15	Bayer Pharmaceuticals Corporation	Quinazoline and quinoline derivative compounds as inhibitors of prolylpeptidase, inducers of apoptosis and cancer treatment agents
AU2003235798A1 (en)	2002-01-10	2003-07-24	F. Hoffmann-La Roche Ag	Use of a gsk-3beta inhibitor in the manufacture of a medicament for increasing bone formation
TWI329105B (en)	2002-02-01	2010-08-21	Rigel Pharmaceuticals Inc	2,4-pyrimidinediamine compounds and their uses
ES2437391T3 (es) *	2002-02-06	2014-01-10	Vertex Pharmaceuticals, Inc.	Compuestos de heteroarilo útiles como inhibidores de GSK-3
WO2003078426A1 (en) *	2002-03-15	2003-09-25	Vertex Pharmaceuticals, Inc.	Azolylaminoazine as inhibitors of protein kinases
AU2003220299A1 (en) *	2002-03-15	2003-09-29	Vertex Pharmaceuticals, Inc.	Azinylaminoazoles as inhibitors of protein kinases
WO2003078427A1 (en)	2002-03-15	2003-09-25	Vertex Pharmaceuticals, Inc.	Azolylaminoazines as inhibitors of protein kinases
WO2003086394A1 (en)	2002-04-08	2003-10-23	Merck & Co., Inc.	Inhibitors of akt activity
WO2003104230A1 (ja)	2002-06-07	2003-12-18	協和醱酵工業株式会社	二環性ピリミジン誘導体
MY141867A (en)	2002-06-20	2010-07-16	Vertex Pharma	Substituted pyrimidines useful as protein kinase inhibitors
JP2005536517A (ja) *	2002-07-23	2005-12-02	スミスクラインビーチャムコーポレーション	キナーゼインヒビターとしてのピラゾロピリミジン
RS51752B (en)	2002-07-29	2011-12-31	Rigel Pharmaceuticals	METHODS OF TREATMENT AND PREVENTION OF AUTOIMMUNE DISEASES WITH 2,4-PYRIMIDINDIAMINE COMPOUNDS
EA200500299A1 (ru)	2002-08-02	2005-08-25	Вертекс Фармасьютикалз Инкорпорейтед	Пиразольные композиции, используемые в качестве ингибиторов gsk-3
EP1739087A1 (en) *	2002-08-02	2007-01-03	Vertex Pharmaceuticals Incorporated	Pyrazole compositions useful as inhibitors of gsk-3
FR2844267B1 (fr) *	2002-09-05	2008-02-15	Aventis Pharma Sa	Nouveaux derives d'aminoindazoles a titre de medicaments et compositions pharmaceutiques les renfermant
PL374946A1 (en)	2002-09-05	2005-11-14	Aventis Pharma S.A.	Novel aminoindazole derivatives as medicines and pharmaceutical compositions containing same
AU2003255482A1 (en) *	2002-10-02	2004-04-23	Merck Patent Gmbh	Use of 4 amino-quinazolines as anti cancer agents
WO2004031161A1 (en)	2002-10-04	2004-04-15	Prana Biotechnology Limited	Neurologically-active compounds
KR100490893B1 (ko) *	2002-10-11	2005-05-23	(주) 비엔씨바이오팜	2-메톡시-1,3,5-트리아진 유도체, 그 제조방법 및 이를 포함하는 항바이러스용 약학적 조성물
GB0226583D0 (en) *	2002-11-14	2002-12-18	Cyclacel Ltd	Compounds
US7462613B2 (en)	2002-11-19	2008-12-09	Sanofi-Aventis Deutschland Gmbh	Pyridazinone derivatives as pharmaceuticals and pharmaceutical compositions containing them
US7309701B2 (en)	2002-11-19	2007-12-18	Sanofi-Aventis Deutschland Gmbh	Pyridazinone derivatives as pharmaceuticals and pharmaceutical compositions containing them
FR2847253B1 (fr) *	2002-11-19	2007-05-18	Aventis Pharma Sa	Nouveaux derives de pyridazinones a titre de medicaments et compositions pharmaceutiques les renfermant
AU2003295776B2 (en)	2002-11-21	2011-05-12	Novartis Vaccines And Diagnostics, Inc.	2,4,6-trisubstituted pyrimidines as phosphotidylinositol (PI) 3-kinase inhibitors and their use in the treatment of cancer
WO2004072029A2 (en) *	2003-02-06	2004-08-26	Vertex Pharmaceuticals Incorporated	Pyrazolopyridazines useful as inhibitors of protein kinases
US7157455B2 (en) *	2003-02-10	2007-01-02	Hoffmann-La Roche Inc.	4-Aminopyrimidine-5-one derivatives
WO2004087679A1 (en) *	2003-04-01	2004-10-14	Aponetics Ag	2, 4, 6-trisubstituted pyrimidine derivatives useful for the treatment of neoplastic and autoimmune diseases
ATE401080T1 (de) *	2003-06-02	2008-08-15	Astrazeneca Ab	(3-((chinazolin-4-yl)amino)-1h-pyrazol-1- yl)acetamid derivate und verwandte verbindungen als aurora kinase inhibitoren zur behandlung von proliferativen erkrankungen wie krebs
EP1633740B1 (en) *	2003-06-19	2011-11-09	GlaxoSmithKline LLC	5-(acylamino)indazole derivatives as kinase inhibitors
TWI372050B (en) *	2003-07-03	2012-09-11	Astex Therapeutics Ltd	(morpholin-4-ylmethyl-1h-benzimidazol-2-yl)-1h-pyrazoles
US8309562B2 (en)	2003-07-03	2012-11-13	Myrexis, Inc.	Compounds and therapeutical use thereof
EP1660092A2 (en) *	2003-07-03	2006-05-31	Myriad Genetics, Inc.	4-arylamino-quinazolines as activators of caspases and inducers of apoptosis
GB0315966D0 (en) *	2003-07-08	2003-08-13	Cyclacel Ltd	Compounds
PL2256106T3 (pl)	2003-07-22	2015-08-31	Astex Therapeutics Ltd	Związki 3,4-pochodne 1h-pirazolu i ich zastosowanie jako kinazy zależne od cyklin (cdk) i modulatory kinazy syntazy glikogenu-3 (gsk-3)
PT1656372E (pt)	2003-07-30	2013-06-27	Rigel Pharmaceuticals Inc	Métodos para o tratamento ou prevenção de doenças autoimunes com compostos de 2,4-pirimidinadiamina
CA2533474A1 (en) *	2003-07-30	2005-02-10	Shudong Wang	2-aminophenyl-4-phenylpyrimidines as kinase inhibitors
US7417726B2 (en) *	2003-09-19	2008-08-26	Applied Biosystems Inc.	Normalization of data using controls
US20050221357A1 (en) *	2003-09-19	2005-10-06	Mark Shannon	Normalization of gene expression data
US20060024690A1 (en) *	2003-09-19	2006-02-02	Kao H P	Normalization of data using controls
US20050124562A1 (en) *	2003-09-23	2005-06-09	Joseph Guiles	Bis-quinazoline compounds for the treatment of bacterial infections
WO2005040159A1 (en)	2003-10-17	2005-05-06	Astrazeneca Ab	4-(pyrazol-3-ylamino) pyrimidine derivatives for use in the treatment of cancer
JP2007513184A (ja) *	2003-12-04	2007-05-24	バーテックス　ファーマシューティカルズ　インコーポレイテッド	プロテインキナーゼのインヒビターとして有用なキノキサリン
AU2004297241A1 (en) *	2003-12-09	2005-06-23	Vertex Pharmaceuticals Incorporated	Naphthyridine derivatives and their use as modulators of muscarinic receptors
WO2005061519A1 (en)	2003-12-19	2005-07-07	Takeda San Diego, Inc.	Kinase inhibitors
TW200530235A (en)	2003-12-24	2005-09-16	Renovis Inc	Bicycloheteroarylamine compounds as ion channel ligands and uses thereof
EP1745034A1 (en) *	2004-02-11	2007-01-24	Amgen Inc.	Vanilloid receptor ligands and their use in treatments
WO2005083105A2 (en) *	2004-02-26	2005-09-09	Bayer Healthcare Ag	Diagnostics and therapeutics for diseases associated with glycogen synthase kinase 3 beta (gsk3b)
CA2560111A1 (en) *	2004-03-15	2005-09-22	Takeda Pharmaceutical Company Limited	Aminophenylpropanoic acid derivative
US7897607B2 (en) *	2004-04-07	2011-03-01	Takeda Pharmaceutical Company Limited	Cyclic compounds
US20090227648A1 (en) *	2004-04-21	2009-09-10	Astrazeneca Ab	Pyrazole derivatives useful for the treatment of cancer
JP2007533753A (ja) *	2004-04-23	2007-11-22	タケダサンディエゴインコーポレイテッド	インドール誘導体及びキナーゼ阻害剤としてのその使用
EP1751136B1 (en) *	2004-05-07	2014-07-02	Amgen Inc.	Nitrogenated heterocyclic derivatives as protein kinase modulators and use for the treatment of angiogenesis and cancer
US7793137B2 (en)	2004-10-07	2010-09-07	Cisco Technology, Inc.	Redundant power and data in a wired data telecommunincations network
AU2012200416B2 (en) *	2004-05-14	2014-07-31	Millennium Pharmaceuticals, Inc.	"Compounds and methods for inhibiting mitotic progression by inhibition of Aurora kinase"
PL1905773T3 (pl) *	2004-05-14	2012-12-31	Millennium Pharm Inc	Związki i sposoby hamowania progresji mitotycznej poprzez hamowanie kinazy aurora
US20050255485A1 (en) *	2004-05-14	2005-11-17	Livak Kenneth J	Detection of gene duplications
DE602005015319D1 (de) *	2004-05-14	2009-08-20	Vertex Pharma	Prodrugs von als erk-proteinkinase-inhibitoren wirkenden pyrrolylpyrimidinen
HRP20080120T5 (hr) *	2004-05-14	2012-07-31	Millennium@Pharmaceuticals	Spojevi i postupci za inhibiciju napredovanja mitoze s pomoću inhibicije aurora kinaze
WO2005112923A2 (en) *	2004-05-20	2005-12-01	Bayer Pharmaceuticals Corporation	5-anilino-4-heteroarylpyrazole derivatives useful for the treatment of diabetes
JP2008500588A (ja) *	2004-05-27	2008-01-10	イー・アイ・デュポン・ドウ・ヌムール・アンド・カンパニー	フォトポリマー保護層用現像剤
TW200612948A (en) *	2004-07-01	2006-05-01	Synta Pharmaceuticals Corp	2-substituted heteroaryl compounds
JP2008505907A (ja) *	2004-07-06	2008-02-28	アンジオンバイオメディカコーポレイション	癌治療を目的として肝細胞増殖因子およびｃ−ｍｅｔ活性を調整するキナゾリンモジュレーター
WO2006023931A2 (en)	2004-08-18	2006-03-02	Takeda San Diego, Inc.	Kinase inhibitors
US7285569B2 (en)	2004-09-24	2007-10-23	Hoff Hoffmann-La Roche Inc.	Tricycles, their manufacture and use as pharmaceutical agents
AR050948A1 (es)	2004-09-24	2006-12-06	Hoffmann La Roche	Derivados de ftalazinona; su obtencion y su utilizacion en la fabricacion de medicamentos para el tratamiento del cancer.
BRPI0516746A (pt) *	2004-09-30	2008-09-23	Tibotec Pharm Ltd	5-heterociclil pirimidinas para inibição de hiv
TW200626561A (en) *	2004-09-30	2006-08-01	Tibotec Pharm Ltd	HIV inhibiting 5-substituted pyrimidines
JP5162245B2 (ja) *	2004-09-30	2013-03-13	テイボテク・フアーマシユーチカルズ	Ｈｉｖ阻害性５−炭素環または複素環置換ピリミジン
EP1812439B2 (en)	2004-10-15	2017-12-06	Takeda Pharmaceutical Company Limited	Kinase inhibitors
WO2006046734A2 (ja) *	2004-10-29	2006-05-04	Banyu Pharma Co Ltd	オーロラa選択的阻害作用を有する新規アミノピリジン誘導体
US7491720B2 (en)	2004-10-29	2009-02-17	Banyu Pharmaceutical Co., Ltd.	Aminopyridine derivatives having Aurora A selective inhibitory action
EP1809290A2 (en)	2004-11-03	2007-07-25	Vertex Pharmaceuticals Incorporated	Pyrimidine derivatives as ion channel modulators and methods of use
AU2005306458B2 (en) *	2004-11-17	2011-02-17	Miikana Therapeutics, Inc.	Kinase inhibitors
ATE540035T1 (de)	2004-11-24	2012-01-15	Rigel Pharmaceuticals Inc	Spiro-2,4-pyrimidindiamin-verbindungen und ihre verwendungen
US20060128710A1 (en) *	2004-12-09	2006-06-15	Chih-Hung Lee	Antagonists to the vanilloid receptor subtype 1 (VR1) and uses thereof
CA2588220A1 (en) *	2004-12-23	2006-06-29	Pfizer Products Inc.	Heteroaromatic derivatives useful as anticancer agents
US8211929B2 (en)	2004-12-30	2012-07-03	Exelixis, Inc.	Pyrimidine derivatives as kinase modulators and method of use
WO2006070195A1 (en) *	2004-12-30	2006-07-06	Astex Therapeutics Limited	Pyrazole compounds that modulate the activity of cdk, gsk and aurora kinases
CA2592900A1 (en)	2005-01-03	2006-07-13	Myriad Genetics Inc.	Nitrogen containing bicyclic compounds and therapeutical use thereof
US8258145B2 (en)	2005-01-03	2012-09-04	Myrexis, Inc.	Method of treating brain cancer
EP1856135B1 (en)	2005-01-19	2009-12-09	Rigel Pharmaceuticals, Inc.	Prodrugs of 2,4-pyrimidinediamine compounds and their uses
AR054425A1 (es) *	2005-01-21	2007-06-27	Astex Therapeutics Ltd	Sales de adicion de piperidin 4-il- amida de acido 4-(2,6-dicloro-benzoilamino) 1h-pirazol-3-carboxilico.
US8404718B2 (en)	2005-01-21	2013-03-26	Astex Therapeutics Limited	Combinations of pyrazole kinase inhibitors
MX2007009017A (es) *	2005-01-26	2007-09-19	Schering Corp	Derivados de 3-(indazol-5-il)-(1,2,4)triazina y compuestos relacionados como inhibidores de proteina cinasa para el tratamiento de cancer.
HRP20110962T1 (hr)	2005-02-04	2012-01-31	Astrazeneca Ab	Derivati pirazolil-aminopiridina korisni kao inhibitori kinaze
NZ561525A (en) *	2005-02-16	2010-11-26	Astrazeneca Ab	Benzimidazole compounds and analogues, containing a pyrazole ring, for inhibition of Trk activity, affecting cancer
BRPI0608160A2 (pt) *	2005-02-16	2010-11-09	Astrazeneca Ab	anticorpo isolado, célula hospedeira, método de inibir o crescimento de células psma+, e, uso de um anticorpo anti-psma defucosilado
MX2007011316A (es) *	2005-03-15	2007-11-12	Irm Llc	Compuestos y composiciones como inhibidores de cinasa de proteina.
JP2008534481A (ja) *	2005-03-23	2008-08-28	アストラゼネカアクチボラグ	インスリン様増殖因子−１受容体活性の阻害剤としての２−アゼチジニル−４−（１ｈ−ピラゾール−３−イルアミノ）ピリミジン
US7297700B2 (en)	2005-03-24	2007-11-20	Renovis, Inc.	Bicycloheteroaryl compounds as P2X7 modulators and uses thereof
US20080167297A1 (en) *	2005-04-05	2008-07-10	Astrazeneca Ab	Pyrimidine Derivatives for Use as Anticancer Agents
GB0507347D0 (en) *	2005-04-12	2005-05-18	Astrazeneca Ab	Chemical compounds
AU2006233537A1 (en)	2005-04-14	2006-10-19	F. Hoffmann-La Roche Ag	Aminopyrazole derivatives, their manufacture and use as pharmaceutical agents
EP1877057A1 (en) *	2005-04-27	2008-01-16	AstraZeneca AB	Use of pyrazolyl-pyrimidine derivatives in the treatment of pain
US7928126B2 (en)	2005-04-28	2011-04-19	Mitsubishi Tanabe Pharma Corporation	Cyanopyridine derivative and use thereof as medicine
EP1885369B1 (en)	2005-05-04	2015-09-23	Evotec AG	Fused heterocyclic compounds, and compositions and uses thereof
WO2006117212A2 (en)	2005-05-04	2006-11-09	Develogen Aktiengesellschaft	Use of gsk-3 inhibitors for preventing and treating pancreatic autoimmune disorders
WO2006117560A1 (en) *	2005-05-05	2006-11-09	Astrazeneca Ab	Pyrazolyl-amino- substituted pyrimidines and their use in the treatment of cancer
JP2008540622A (ja) *	2005-05-16	2008-11-20	アストラゼネカアクチボラグ	化合物
NZ563454A (en)	2005-06-08	2011-03-31	Rigel Pharmaceuticals Inc	2,4-diaminopyrimidine derivatives for inhibition of the JAK pathway
US20070203161A1 (en)	2006-02-24	2007-08-30	Rigel Pharmaceuticals, Inc.	Compositions and methods for inhibition of the jak pathway
US8193206B2 (en)	2005-06-14	2012-06-05	Taigen Biotechnology Co., Ltd.	Pyrimidine compounds
JP5118029B2 (ja)	2005-06-14	2013-01-16	タイゲンバイオテクノロジーカンパニー，リミテッド	ピリミジン化合物
EP1746096A1 (en)	2005-07-15	2007-01-24	4Sc Ag	2-Arylbenzothiazole analogues and uses thereof in the treatment of cancer
ATE542814T1 (de) *	2005-08-18	2012-02-15	Vertex Pharma	Pyrazinkinaseinhibitoren
WO2007023382A2 (en) *	2005-08-25	2007-03-01	Pfizer Inc.	Pyrimidine amino pyrazole compounds, potent kinase inhibitors
AU2006282896A1 (en)	2005-08-26	2007-03-01	Braincells, Inc.	Neurogenesis by muscarinic receptor modulation
EP2258359A3 (en)	2005-08-26	2011-04-06	Braincells, Inc.	Neurogenesis by muscarinic receptor modulation with sabcomelin
CN101316587B (zh) *	2005-09-30	2013-04-03	迈卡纳治疗股份有限公司	取代的吡唑化合物
AU2006297120B2 (en) *	2005-09-30	2011-05-19	Miikana Therapeutics, Inc.	Substituted pyrazole compounds
US8119655B2 (en)	2005-10-07	2012-02-21	Takeda Pharmaceutical Company Limited	Kinase inhibitors
AU2006304787A1 (en)	2005-10-21	2007-04-26	Braincells, Inc.	Modulation of neurogenesis by PDE inhibition
WO2007049041A1 (en)	2005-10-28	2007-05-03	Astrazeneca Ab	4- (3-aminopyrazole) pyrimidine derivatives for use as tyrosine kinase inhibitors in the treatment of cancer
EP2314289A1 (en)	2005-10-31	2011-04-27	Braincells, Inc.	Gaba receptor mediated modulation of neurogenesis
JP5137207B2 (ja) *	2005-11-01	2013-02-06	アレイバイオファーマ、インコーポレイテッド	グルコキナーゼ活性化因子
NZ606259A (en) *	2005-11-03	2014-06-27	Vertex Pharma	Aminopyrimidines useful as kinase inhibitors
WO2007059299A1 (en) *	2005-11-16	2007-05-24	Vertex Pharmaceuticals Incorporated	Aminopyrimidines useful as kinase inhibitors
US8546404B2 (en)	2005-12-13	2013-10-01	Merck Sharp & Dohme	Compounds that are ERK inhibitors
US7572809B2 (en) *	2005-12-19	2009-08-11	Hoffmann-La Roche Inc.	Isoquinoline aminopyrazole derivatives
JP5474354B2 (ja)	2005-12-30	2014-04-16	アステックス、セラピューティックス、リミテッド	医薬化合物
WO2007081978A2 (en) *	2006-01-11	2007-07-19	Angion Biomedica Corporation	Modulators of hepatocyte growth factor / c-met activity
JO2660B1 (en)	2006-01-20	2012-06-17	نوفارتيس ايه جي	Pi-3 inhibitors and methods of use
ATE485268T1 (de)	2006-02-16	2010-11-15	Schering Corp	Pyrrolidin-derivate als erk-hemmer
US20100216734A1 (en)	2006-03-08	2010-08-26	Braincells, Inc.	Modulation of neurogenesis by nootropic agents
PE20080145A1 (es)	2006-03-21	2008-02-11	Janssen Pharmaceutica Nv	Tetrahidro-pirimidoazepinas como moduladores de trpv1
KR20080114741A (ko)	2006-03-30	2008-12-31	티보텍 파마슈티칼즈 리미티드	Ｈｉｖ를 억제하는 5-아미도 치환 피리미딘
WO2007117465A2 (en) *	2006-03-31	2007-10-18	Abbott Laboratories	Indazole compounds
US20090286803A1 (en)	2006-04-07	2009-11-19	Manley Paul W	Combination comprising a) a pyrimidylaminobenzamide compound, and b) a thr315lle kinase inhibitor
AU2007240120A1 (en)	2006-04-14	2007-10-25	Prana Biotechnology Ltd	Method of treatment of age-related macular degeneration (AMD)
CA2650572C (en) *	2006-04-27	2013-09-10	Banyu Pharmaceutical Co., Ltd.	Novel aminopyridine derivatives having aurora a selective inhibitory action
AU2007249435A1 (en)	2006-05-09	2007-11-22	Braincells, Inc.	5 HT receptor mediated neurogenesis
JP2009536669A (ja)	2006-05-09	2009-10-15	ブレインセルス，インコーポレイティド	アンジオテンシン調節による神経新生
CN103070854A (zh) *	2006-06-27	2013-05-01	武田药品工业株式会社	稠环化合物
US20110159111A1 (en) *	2006-06-29	2011-06-30	Astex Therapeutics Limited	Pharmaceutical combinations
US8435970B2 (en)	2006-06-29	2013-05-07	Astex Therapeutics Limited	Pharmaceutical combinations of 1-cyclopropyl-3-[3-(5-morpholin-4-ylmethyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-urea
WO2008001070A1 (en) *	2006-06-30	2008-01-03	Astrazeneca Ab	Pyrimidine derivatives useful in the treatment of cancer
CN101484426A (zh) *	2006-06-30	2009-07-15	协和发酵麒麟株式会社	Aurora抑制剂
AU2007269540B2 (en)	2006-07-05	2013-06-27	Exelixis, Inc.	Methods of using IGF1R and Abl kinase modulators
MX2009001043A (es)	2006-08-08	2009-02-06	Sanofi Aventis	Imidazolidina-2,4-dionas sustituidas con arilaminoarilalquilo, procedimiento para preparalas, medicamentos que comprenden estos compuestos y su uso.
JP2010500352A (ja) *	2006-08-09	2010-01-07	ミレニアム・ファーマシューティカルズ・インコーポレイテッド	有糸分裂の進行を阻止するためのピリドベンゾアゼピン化合物および方法
US7635168B2 (en) *	2006-08-11	2009-12-22	Hall David R	Degradation assembly shield
JP2008081492A (ja)	2006-08-31	2008-04-10	Banyu Pharmaceut Co Ltd	オーロラａ選択的阻害作用を有する新規アミノピリジン誘導体
EP2068872A1 (en) *	2006-09-08	2009-06-17	Braincells, Inc.	Combinations containing a 4-acylaminopyridine derivative
US20100184806A1 (en)	2006-09-19	2010-07-22	Braincells, Inc.	Modulation of neurogenesis by ppar agents
EP2223925A1 (en) *	2006-10-09	2010-09-01	Takeda Pharmaceutical Company Limited	Kinase inhibitors
SG175609A1 (en)	2006-10-09	2011-11-28	Takeda Pharmaceutical	Kinase inhibitors
JP5528806B2 (ja)	2006-10-12	2014-06-25	アステックス、セラピューティックス、リミテッド	複合薬剤
WO2008044045A1 (en)	2006-10-12	2008-04-17	Astex Therapeutics Limited	Pharmaceutical combinations
WO2008053812A1 (fr) *	2006-10-27	2008-05-08	Mitsubishi Tanabe Pharma Corporation	Dérivé de cyanopyridine et son utilisation médicale
MX2009004807A (es) *	2006-11-02	2009-06-15	Vertex Pharma	Aminopiridinas y aminopirimidinas utiles como inhibidores de proteina cinasa.
CL2007003244A1 (es) *	2006-11-16	2008-04-04	Millennium Pharm Inc	Compuestos derivados de pirimido[5,4-d][2]benzazepina; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento del cancer.
DE602007007985D1 (de) *	2006-12-19	2010-09-02	Vertex Pharma	Als inhibitoren von proteinkinasen geeignete aminopyrimidine
ES2618057T3 (es) *	2006-12-29	2017-06-20	Janssen Sciences Ireland Uc	Pirimidinas 5,6-sustituidas inhibidoras del VIH
CA2674178C (en) *	2006-12-29	2015-11-10	Tibotec Pharmaceuticals Ltd.	Hiv inhibiting 6-substituted pyrimidines
MX2009008341A (es)	2007-02-06	2009-08-12	Novartis Ag	Inhibidores de cinasa de pi3 y metodos para su uso.
KR20090115866A (ko)	2007-03-05	2009-11-09	교와 핫꼬 기린 가부시키가이샤	의약 조성물
EP2134707B1 (en) *	2007-03-09	2013-09-11	Vertex Pharmaceuticals, Inc.	Aminopyrimidines useful as inhibitors of protein kinases
NZ579483A (en)	2007-03-09	2012-07-27	Vertex Pharma	Aminopyridines useful as inhibitors of protein kinases
WO2008112651A2 (en) *	2007-03-09	2008-09-18	Vertex Pharmaceuticals Incorporated	Aminopyrimidines useful as inhibitors of protein kinases
AU2008228963A1 (en) *	2007-03-20	2008-09-25	Vertex Pharmaceuticals Incorporated	Aminopyrimidines useful as kinase inhibitors
WO2008117050A1 (en) *	2007-03-27	2008-10-02	Astrazeneca Ab	Pyrazolyl-amino-substituted pyrazines and their use for the treatment of cancer
CN101679386A (zh) *	2007-04-13	2010-03-24	沃泰克斯药物股份有限公司	可用作激酶抑制剂的氨基嘧啶类化合物
WO2008129255A1 (en) *	2007-04-18	2008-10-30	Astrazeneca Ab	5-aminopyrazol-3-yl-3h-imidazo [4,5-b] pyridine derivatives and their use for the treatment of cancer
EP2146779B1 (en)	2007-04-18	2016-08-10	Pfizer Products Inc.	Sulfonyl amide derivatives for the treatment of abnormal cell growth
MX2009011811A (es) *	2007-05-02	2010-01-14	Vertex Pharma	Aminopirimidinas utiles como inhibidores de cinasa.
WO2008137619A2 (en)	2007-05-02	2008-11-13	Vertex Pharmaceuticals Incorporated	Thiazoles and pyrazoles useful as kinase inhibitors
WO2008137621A1 (en) *	2007-05-02	2008-11-13	Vertex Pharmaceuticals Incorporated	Aminopyrimidines useful as kinase inhibitors
UA99459C2 (en)	2007-05-04	2012-08-27	Астразенека Аб	9-(pyrazol-3-yl)- 9h-purine-2-amine and 3-(pyraz0l-3-yl)-3h-imidazo[4,5-b]pyridin-5-amine derivatives and their use for the treatment of cancer
ES2369596T3 (es) *	2007-05-04	2011-12-02	Astrazeneca Ab	Derivados de amino-tiazolil-pirimidina y su uso para el tratamiento del cáncer.
WO2008147626A2 (en) *	2007-05-24	2008-12-04	Vertex Pharmaceuticals Incorporated	Thiazoles and pyrazoles useful as kinase inhibitors
KR101294731B1 (ko) *	2007-06-04	2013-08-16	삼성디스플레이 주식회사	어레이 기판, 이를 갖는 표시패널 및 이의 제조방법
AU2008262291A1 (en) *	2007-06-11	2008-12-18	Miikana Therapeutics, Inc.	Substituted pyrazole compounds
WO2009008992A2 (en) *	2007-07-06	2009-01-15	Osi Pharmaceuticals Inc.	Combination anti-cancer therapy comprising an inhibitor of both mtorc1 and mt0rc2
WO2009007753A2 (en) *	2007-07-11	2009-01-15	Astrazeneca Ab	4- (3-aminopyrazole) -pyrimidine derivativee and their use as tyrosine kinase inhibitors for the treatment of cancer
EP2175933B1 (en) *	2007-07-25	2012-08-22	Bristol-Myers Squibb Company	Triazine kinase inhibitors
WO2009013545A2 (en) *	2007-07-26	2009-01-29	Astrazeneca Ab	Chemical compounds
TW200906818A (en) *	2007-07-31	2009-02-16	Astrazeneca Ab	Chemical compounds
CN101790532B (zh) *	2007-07-31	2013-11-20	沃泰克斯药物股份有限公司	5-氟-1H-吡唑并[3，4-b]吡啶-3-胺及其衍生物的制备方法
EP2025674A1 (de)	2007-08-15	2009-02-18	sanofi-aventis	Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
WO2009027736A2 (en) *	2007-08-27	2009-03-05	Astrazeneca Ab	2,4 diaminopyrimid'lnes for the treatment of myeloproliferative disorders and cancer
HRP20120814T1 (hr)	2007-09-21	2012-11-30	Array Biopharma, Inc.	Derivati piridin-1,2,4-tiadiazola kao aktivatori glukokinaze, namijenjeni lijeäśenju dijabetesa melitusa
RS53180B (en)	2007-10-11	2014-06-30	Glaxosmithkline Llc	NEW SEH INHIBITORS AND THEIR USE
CL2008003749A1 (es)	2007-12-17	2010-01-15	Janssen Pharmaceutica Nv	Compuestos derivados de imidazol, oxazol, y tiazol pirimidina, moduladores de trpv1, proceso de preparacion, composicion farmaceutica y su uso en el tratamiento de enfermedades, trastornos o condicion de dolor, prurito, artritis, tos, asma, trastorno del oido interno y enfermedad inflamatoria intestinal, entre otras.
US20090270418A1 (en) *	2008-01-09	2009-10-29	Marianne Sloss	Pyrazole pyrazine amine compounds as kinase inhibitors, compositions thereof and methods of treatment therewith
EP2242745A1 (de) *	2008-02-07	2010-10-27	Sanofi-Aventis	Neue phenyl-substituierte imidazolidine, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
SG188179A1 (en)	2008-02-21	2013-03-28	Merck Sharp & Dohme	Compounds that are erk inhibitors
CA2714215A1 (en)	2008-02-22	2009-08-27	Banyu Pharmaceutical Co., Ltd.	Novel aminopyridine derivatives having aurora a selective inhibitory action
AU2008355098B2 (en)	2008-04-21	2012-11-15	Gpcr Therapeutics, Inc	Heterocyclic compounds
WO2010011411A1 (en)	2008-05-27	2010-01-28	The Trustees Of Columbia University In The City Of New York	Systems, methods, and media for detecting network anomalies
TW201006830A (en) *	2008-06-11	2010-02-16	Astrazeneca Ab	Chemical compounds
TW201014822A (en)	2008-07-09	2010-04-16	Sanofi Aventis	Heterocyclic compounds, processes for their preparation, medicaments comprising these compounds, and the use thereof
ES2432821T3 (es) *	2008-07-31	2013-12-05	Genentech, Inc.	Compuestos de pirimidina, composiciones y métodos de utilización
JP2012501971A (ja) *	2008-09-03	2012-01-26	バーテックスファーマシューティカルズインコーポレイテッド	共結晶および共結晶を含む薬学的処方物
US20100185419A1 (en) *	2008-09-05	2010-07-22	Avila Therapeutics, Inc.	Algorithm for designing irreversible inhibitors
EP2340248B1 (en) *	2008-09-15	2017-05-31	The Regents of The University of California	Methods and compositions for modulating ire1, src, and abl activity
CA2737217A1 (en) *	2008-09-30	2010-04-08	Astrazeneca Ab	Heterocyclic jak kinase inhibitors
US8759362B2 (en) *	2008-10-24	2014-06-24	Purdue Pharma L.P.	Bicycloheteroaryl compounds and their use as TRPV1 ligands
WO2010056758A1 (en) *	2008-11-12	2010-05-20	Yangbo Feng	Quinazoline derivatives as kinase inhibitors
TW201021855A (en)	2008-11-13	2010-06-16	Taigen Biotechnology Co Ltd	Lyophilization formulation
WO2010068601A1 (en)	2008-12-08	2010-06-17	Sanofi-Aventis	A crystalline heteroaromatic fluoroglycoside hydrate, processes for making, methods of use and pharmaceutical compositions thereof
PA8851101A1 (es)	2008-12-16	2010-07-27	Lilly Co Eli	Compuesto amino pirazol
WO2010070060A1 (en)	2008-12-19	2010-06-24	Nerviano Medical Sciences S.R.L.	Bicyclic pyrazoles as protein kinase inhibitors
CA2747326C (en)	2008-12-22	2017-05-16	Millennium Pharmaceuticals, Inc.	Combination of aurora kinase inhibitors and anti-cd20 antibodies
US8809343B2 (en)	2008-12-26	2014-08-19	Fudan University	Pyrimidine derivative, preparation method and use thereof
WO2010099217A1 (en)	2009-02-25	2010-09-02	Braincells, Inc.	Modulation of neurogenesis using d-cycloserine combinations
CN102395576A (zh) *	2009-02-27	2012-03-28	埃姆比特生物科学公司	调控jak激酶的喹唑啉衍生物和其使用方法
CA2660962A1 (en)	2009-03-31	2010-09-30	Astellas Pharma Inc.	Novel pharmaceutical composition for treatment of schizophrenia
US8399663B2 (en)	2009-04-03	2013-03-19	Astellas Pharma Inc.	Salt of 1,3,5-triazine-2,4,6-triamine derivative
JO3635B1 (ar)	2009-05-18	2020-08-27	Millennium Pharm Inc	مركبات صيدلانية صلبة وطرق لانتاجها
BRPI1010881A2 (pt) *	2009-06-08	2016-05-31	California Capital Equity Llc	derivados de triazina e suas aplicações terapêuticas.
BRPI1010887A2 (pt) *	2009-06-08	2016-12-27	California Capital Equity Llc	derivados de triazina e suas aplicações terapêuticas.
CA2765050A1 (en) *	2009-06-09	2010-12-16	California Capital Equity, Llc	Ureidophenyl substituted triazine derivatives and their therapeutical applications
WO2010144423A1 (en) *	2009-06-09	2010-12-16	Abraxis Bioscience, Llc	Styryl-triazine derivatives and their therapeutical applications
CN102573480B (zh) *	2009-06-09	2015-06-10	加利福尼亚资本权益有限责任公司	三嗪衍生物及其治疗应用
KR20120026612A (ko)	2009-06-09	2012-03-19	아브락시스 바이오사이언스, 엘엘씨	벤질 치환 트리아진 유도체와 이들의 치료적 용도
US20120172384A1 (en) *	2009-06-18	2012-07-05	Mihiro Sunose	Heterocyclylaminopyrimidines as kinase inhibitors
US8637525B2 (en)	2009-07-31	2014-01-28	Bristol-Myers Squibb Company	Compounds for the reduction of beta-amyloid production
TWI468402B (zh) *	2009-07-31	2015-01-11	必治妥美雅史谷比公司	降低β－類澱粉生成之化合物
JP2013503135A (ja)	2009-08-26	2013-01-31	サノフイ	新規な結晶性複素芳香族フルオログリコシド水和物、その化合物を含んでなる医薬及びその使用
RU2012114902A (ru)	2009-09-16	2013-10-27	Авила Терапьютикс, Инк.	Конъюгаты и ингибиторы протеинкиназы
EP2467065B1 (en) *	2009-11-13	2020-01-08	Intuitive Surgical Operations, Inc.	End effector with redundant closing mechanisms
EP2937345B1 (en)	2009-12-29	2018-03-21	Dana-Farber Cancer Institute, Inc.	Type ii raf kinase inhibitors
US20110269244A1 (en)	2009-12-30	2011-11-03	Petter Russell C	Ligand-directed covalent modification of protein
SA111320200B1 (ar) *	2010-02-17	2014-02-16	ديبيوفارم اس ايه	مركبات ثنائية الحلقة واستخداماتها كمثبطات c-src/jak مزدوجة
BR112012020557A8 (pt)	2010-02-19	2018-01-02	Millennium Pharm Inc	formas cristalinas de 4-{[9-cloro-7-(2-flúor-6-metoifenil)-5h-pirimido[5,4-d][2]benzazepin-2-il]amino}-2-metoxibenzoato de sódio
WO2011107494A1 (de)	2010-03-03	2011-09-09	Sanofi	Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung
US20130059830A1 (en) *	2010-05-20	2013-03-07	Fa-Xiang Ding	Novel prolylcarboxypeptidase inhibitors
BR112012029647A2 (pt)	2010-05-21	2016-08-02	Chemilia Ab	novos derivados de pirimidinas
KR101531448B1 (ko)	2010-06-04	2015-06-24	에프. 호프만-라 로슈 아게	Lrrk2 조절제로서의 아미노피리미딘 유도체
US8933024B2 (en)	2010-06-18	2015-01-13	Sanofi	Azolopyridin-3-one derivatives as inhibitors of lipases and phospholipases
US8530413B2 (en)	2010-06-21	2013-09-10	Sanofi	Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments
TW201215387A (en)	2010-07-05	2012-04-16	Sanofi Aventis	Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament
TW201215388A (en)	2010-07-05	2012-04-16	Sanofi Sa	(2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments
TW201221505A (en)	2010-07-05	2012-06-01	Sanofi Sa	Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament
EP3375775A1 (en)	2010-07-29	2018-09-19	Oryzon Genomics, S.A.	Arylcyclopropylamine based demethylase inhibitors of lsd1 and their medical use
WO2012030944A2 (en) *	2010-09-01	2012-03-08	Ambit Biosciences Corporation	Quinoline and isoquinoline compounds and methods of use thereof
WO2012030910A1 (en) *	2010-09-01	2012-03-08	Ambit Biosciences Corporation	2-cycloquinazoline derivatives and methods of use thereof
ES2619850T3 (es) *	2010-09-01	2017-06-27	Ambit Biosciences Corporation	Sales de hidrobromuro de una pirazolilaminoquinazolina
US20130225614A1 (en) *	2010-09-01	2013-08-29	Ambit Biosciences Corporation	4-azolylaminoquinazoline derivatives and methods of use thereof
EP2611502A1 (en) *	2010-09-01	2013-07-10	Ambit Biosciences Corporation	Adenosine a3 receptor modulating compounds and methods of use thereof
JP5932794B2 (ja) *	2010-09-01	2016-06-08	アムビトビオスシエンセスコルポラチオン	光学活性のあるピラゾリルアミノキナゾリン及びその医薬組成物及び使用方法
CN103298805A (zh) *	2010-09-01	2013-09-11	埃姆比特生物科学公司	喹唑啉化合物及其使用方法
WO2012059932A1 (en)	2010-11-01	2012-05-10	Aurigene Discovery Technologies Limited	2, 4 -diaminopyrimidine derivatives as protein kinase inhibitors
AU2011328139A1 (en)	2010-11-10	2013-04-04	F. Hoffmann-La Roche Ag	Pyrazole aminopyrimidine derivatives as LRRK2 modulators
WO2012120055A1 (de)	2011-03-08	2012-09-13	Sanofi	Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
WO2012120051A1 (de)	2011-03-08	2012-09-13	Sanofi	Mit adamantan- oder noradamantan substituierte benzyl-oxathiazinderivate, diese verbindungen enthaltende arzneimittel und deren verwendung
US8871758B2 (en)	2011-03-08	2014-10-28	Sanofi	Tetrasubstituted oxathiazine derivatives, method for producing them, their use as medicine and drug containing said derivatives and the use thereof
WO2012120054A1 (de)	2011-03-08	2012-09-13	Sanofi	Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
US8895547B2 (en)	2011-03-08	2014-11-25	Sanofi	Substituted phenyl-oxathiazine derivatives, method for producing them, drugs containing said compounds and the use thereof
WO2012120053A1 (de)	2011-03-08	2012-09-13	Sanofi	Verzweigte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
WO2012120052A1 (de)	2011-03-08	2012-09-13	Sanofi	Mit carbozyklen oder heterozyklen substituierte oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
WO2012120050A1 (de)	2011-03-08	2012-09-13	Sanofi	Neue substituierte phenyl-oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
EP2683701B1 (de)	2011-03-08	2014-12-24	Sanofi	Mit benzyl- oder heteromethylengruppen substituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
WO2012127032A1 (en)	2011-03-24	2012-09-27	Chemilia Ab	Novel pyrimidine derivatives
KR20140062079A (ko) *	2011-08-25	2014-05-22	에프. 호프만-라 로슈 아게	세린/트레오닌 pak1 억제제
WO2013037390A1 (en)	2011-09-12	2013-03-21	Sanofi	6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
WO2013042006A1 (en)	2011-09-22	2013-03-28	Pfizer Inc.	Pyrrolopyrimidine and purine derivatives
WO2013045413A1 (en)	2011-09-27	2013-04-04	Sanofi	6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
GEP20166432B (en)	2011-09-27	2016-02-10	Novartis Ag	3-pyrimidin-4-yl-oxazolidin-2-ones as inhibitors of mutant idh
EP2822935B1 (en)	2011-11-17	2019-05-15	Dana-Farber Cancer Institute, Inc.	Inhibitors of c-jun-n-terminal kinase (jnk)
KR20140103972A (ko)	2011-12-22	2014-08-27	에프. 호프만-라 로슈 아게	세린/트레오닌 키나아제 억제제로서의 2,4-다이아민-피리미딘 유도체
MX2014009933A (es) *	2012-02-17	2015-12-16	Abbvie Inc	Diaminopirimidinas utiles como inhibidores del virus sincitial respiratorio humano (rsv).
UY34632A (es)	2012-02-24	2013-05-31	Novartis Ag	Compuestos de oxazolidin- 2- ona y usos de los mismos
TWI485146B (zh) *	2012-02-29	2015-05-21	Taiho Pharmaceutical Co Ltd	Novel piperidine compounds or salts thereof
EP2834232A1 (en)	2012-03-16	2015-02-11	Axikin Pharmaceuticals, Inc.	3,5-diaminopyrazole kinase inhibitors
US20130303519A1 (en)	2012-03-20	2013-11-14	Millennium Pharmaceuticals, Inc.	Methods of treating cancer using aurora kinase inhibitors
CN106986863B (zh)	2012-04-24	2019-12-31	沃泰克斯药物股份有限公司	Dna-pk抑制剂
EP2855451B1 (en) *	2012-05-24	2017-10-04	Cellzome Limited	Heterocyclyl pyrimidine analogues as tyk2 inhibitors
WO2014004376A2 (en)	2012-06-26	2014-01-03	Del Mar Pharmaceuticals	Methods for treating tyrosine-kinase-inhibitor-resistant malignancies in patients with genetic polymorphisms or ahi1 dysregulations or mutations employing dianhydrogalactitol, diacetyldianhydrogalactitol, dibromodulcitol, or analogs or derivatives thereof
CA2878621C (en) *	2012-07-10	2020-09-15	Ares Trading S.A.	Pyrimidine pyrazolyl derivatives
BR112015005489B1 (pt) *	2012-09-19	2022-07-12	Taiho Pharmaceutical Co., Ltd.	Composição farmacêutica para administração oral com dissolução e/ou absorção aperfeiçoadas
US9296733B2 (en)	2012-11-12	2016-03-29	Novartis Ag	Oxazolidin-2-one-pyrimidine derivative and use thereof for the treatment of conditions, diseases and disorders dependent upon PI3 kinases
CN103202843B (zh) *	2012-12-31	2015-04-29	刘强	一种嘧啶衍生物在制备预防和/或治疗和/或辅助治疗癌症的药物中的用途
CN103191120B (zh) *	2012-12-31	2015-11-25	刘强	一种嘧啶衍生物在制备预防和/或治疗和/或辅助治疗肿瘤的药物中的用途
CN103059002B (zh) *	2012-12-31	2015-04-22	中山大学	具有Aurora激酶抑制活性的嘧啶衍生物及其制备方法以及应用
CN103910716A (zh) *	2013-01-07	2014-07-09	华东理工大学	2,4-二取代-环烷基[d]嘧啶类化合物及其用途
EP3985003B1 (en)	2013-03-12	2023-08-09	Vertex Pharmaceuticals Incorporated	Dna-pk inhibitors
AU2014229313B2 (en)	2013-03-14	2016-07-28	Novartis Ag	3-pyrimidin-4-yl-oxazolidin-2-ones as inhibitors of mutant IDH
WO2014145485A2 (en)	2013-03-15	2014-09-18	The Trustees Of Columbia University In The City Of New York	Map kinase modulators and uses thereof
WO2014153509A1 (en)	2013-03-22	2014-09-25	Millennium Pharmaceuticals, Inc.	Combination of catalytic mtorc 1/2 inhibitors and selective inhibitors of aurora a kinase
WO2015003355A2 (en) *	2013-07-11	2015-01-15	Agios Pharmaceuticals, Inc.	Therapeutically active compounds and their methods of use
AU2014293011A1 (en)	2013-07-26	2016-03-17	Race Oncology Ltd.	Compositions to improve the therapeutic benefit of bisantrene
WO2015028848A1 (en) *	2013-09-02	2015-03-05	Piramal Enterprises Limited	Bicyclic heterocyclic compounds as multi-kinase inhibitors
NZ631142A (en)	2013-09-18	2016-03-31	Axikin Pharmaceuticals Inc	Pharmaceutically acceptable salts of 3,5-diaminopyrazole kinase inhibitors
MX361488B (es)	2013-10-17	2018-12-07	Vertex Pharma	Cocristales de (s)-n-metil-8-(1-((2'-metil-[4,5'-bipirimidin]-6-il ) amino)propan-2-il)quinolina-4-carboxamida y sus derivados deuterados como inhibidores de proteínas cinasa dependientes de adn (adn-pk).
CN105849099B (zh)	2013-10-18	2020-01-17	达纳-法伯癌症研究所股份有限公司	周期蛋白依赖性激酶7(cdk7)的多环抑制剂
CA2927917C (en)	2013-10-18	2022-08-09	Syros Pharmaceuticals, Inc.	Heteroaromatic compounds useful for the treatment of proliferative diseases
WO2015103355A1 (en)	2014-01-01	2015-07-09	Medivation Technologies, Inc.	Compounds and methods of use
AU2015228369B2 (en)	2014-03-13	2020-05-21	Neuroderm Ltd	DOPA decarboxylase inhibitor compositions
US10258585B2 (en)	2014-03-13	2019-04-16	Neuroderm, Ltd.	DOPA decarboxylase inhibitor compositions
CA2943979A1 (en)	2014-03-28	2015-10-01	Calitor Sciences, Llc	Substituted heteroaryl compounds and methods of use
AU2015239886B2 (en)	2014-04-04	2018-02-01	Iomet Pharma Ltd	Indole derivatives for use in medicine
US20170165230A1 (en)	2014-04-09	2017-06-15	Christopher Rudd	Use of gsk-3 inhibitors or activators which modulate pd-1 or t-bet expression to modulate t cell immunity
CN105367555B (zh) *	2014-08-07	2019-06-25	广东东阳光药业有限公司	取代的杂芳基化合物及其组合物和用途
EP3236959A4 (en)	2014-12-23	2018-04-25	Dana Farber Cancer Institute, Inc.	Inhibitors of cyclin-dependent kinase 7 (cdk7)
MY191736A (en)	2014-12-23	2022-07-13	Axikin Pharmaceuticals Inc	3,5-diaminopyrazole kinase inhibitors
WO2016123627A1 (en) *	2015-01-30	2016-08-04	Vanderbilt University	Isoquiniline and napthalene-substituted compounds as mglur4 allosteric potentiators, compounds, and methods of treating neurological dysfunction
HK1246645A1 (zh)	2015-03-27	2018-09-14	达纳-法伯癌症研究所股份有限公司	細胞周期蛋白依賴性激酶的抑制劑
WO2016166604A1 (en)	2015-04-17	2016-10-20	Ludwig Institute For Cancer Research Ltd	Plk4 inhibitors
BR112017025542A2 (pt)	2015-05-28	2018-08-07	Theravance Biopharma R&D Ip, Llc	compostos de naftiridina como inibidores de quinase jak
JP2018135268A (ja) *	2015-06-05	2018-08-30	大日本住友製薬株式会社	新規ヘテロアリールアミノ−３−ピラゾール誘導体およびその薬理学上許容される塩
US20180207173A1 (en)	2015-07-21	2018-07-26	Millennium Pharmaceuticals, Inc.	Administration of aurora kinase inhibitor and chemotherapeutic agents
EP4019515A1 (en)	2015-09-09	2022-06-29	Dana-Farber Cancer Institute, Inc.	Inhibitors of cyclin-dependent kinases
US9938257B2 (en)	2015-09-11	2018-04-10	Calitor Sciences, Llc	Substituted heteroaryl compounds and methods of use
KR20220100719A (ko) *	2015-12-10	2022-07-15	피티씨 테라퓨틱스, 인크.	헌팅턴병 치료 또는 개선을 위한 조성물
CN105503754B (zh) *	2015-12-11	2017-11-17	浙江大学	2‑氨基‑4‑苄基‑6‑吗啉‑1,3,5‑三嗪及其制备和应用
CN105399695B (zh) *	2015-12-11	2019-04-19	浙江大学	三嗪类化合物及其制备方法和用途
CN105384702B (zh) *	2015-12-11	2018-04-10	浙江大学	三取代均三嗪类化合物及其制备方法
US10894784B2 (en)	2015-12-18	2021-01-19	Bayer Pharma Aktiengesellschaft	Heteroarylbenzimidazole compounds
AU2017233841B9 (en)	2016-03-14	2021-09-09	Afferent Pharmaceuticals Inc.	Pyrimidines and variants thereof, and uses therefor
EP3433258B1 (en)	2016-03-25	2023-07-19	Afferent Pharmaceuticals Inc.	Pyrimidines and variants thereof, and uses therefor
US10028960B2 (en)	2016-04-28	2018-07-24	Theravance Biopharma R&D Ip, Llc	Pyrimidine compounds as JAK kinase inhibitors
WO2017207534A1 (en)	2016-06-03	2017-12-07	Bayer Pharma Aktiengesellschaft	Substituted heteroarylbenzimidazole compounds
EP3518931A4 (en)	2016-09-27	2020-05-13	Vertex Pharmaceuticals Incorporated	Method for treating cancer using a combination of dna-damaging agents and dna-pk inhibitors
US10858319B2 (en)	2016-10-03	2020-12-08	Iomet Pharma Ltd.	Indole derivatives for use in medicine
US10968227B2 (en) *	2016-11-08	2021-04-06	Vanderbilt University	Isoquinoline ether compounds as mGluR4 allosteric potentiators, compositions, and methods of treating neurological dysfunction
CN108239071B (zh) *	2016-12-27	2020-12-04	沈阳药科大学	酰胺及硫代酰胺类衍生物及其制备方法和应用
FR3064275B1 (fr)	2017-03-21	2019-06-07	Arkema France	Procede de chauffage et/ou climatisation d'un vehicule
CR20190580A (es)	2017-05-30	2020-02-10	Basf Se	Compuestos de piridina y pirazina
EP3634953B1 (en)	2017-06-05	2024-01-03	PTC Therapeutics, Inc.	Compounds for treating huntington's disease
CA3067592A1 (en)	2017-06-28	2019-01-03	Ptc Therapeutics, Inc.	Methods for treating huntington's disease
WO2019005980A1 (en)	2017-06-28	2019-01-03	Ptc Therapeutics, Inc.	METHODS OF TREATING HUNTINGTON'S DISEASE
KR102469161B1 (ko)	2017-06-30	2022-11-23	베이징 타이드 파마슈티컬 코퍼레이션 리미티드	Ｒｈｏ-관련 단백질 키나아제 억제제, Ｒｈｏ-관련 단백질 키나아제 억제제를 함유하는 약학 조성물, 제조 방법 및 약학 조성물의 용도
CN117343049A (zh)	2017-06-30	2024-01-05	北京泰德制药股份有限公司	Rho相关蛋白激酶抑制剂、包含其的药物组合物及其制备方法和用途
US10329282B2 (en)	2017-06-30	2019-06-25	Beijing Tide Pharmaceutical Co., Ltd.	Rho-associated protein kinase inhibitor, pharmaceutical composition comprising the same, as well as preparation method and use thereof
EP3676264A1 (en) *	2017-08-28	2020-07-08	Acurastem Inc.	Pikfyve kinase inhibitors
US11440904B2 (en) *	2017-08-28	2022-09-13	Zhihong Chen	Substituted pyrimidines, pharmaceutical compositions and therapeutic methods thereof
SI3672965T1 (sl)	2017-10-27	2022-11-30	Theravance Biopharma R&D Ip, Llc	Pirimidinska spojina kot zaviralec JAK-KINAZE
MX2020004536A (es) *	2017-11-23	2020-08-03	Biomed X Gmbh	Derivados de pirimidina como inhibidores del receptor de tropomiosina quinasa (trka).
EP3720560A4 (en) *	2017-12-06	2022-01-05	Ludwig Institute for Cancer Research Ltd	METHOD OF TREATMENT OF CANCER WITH PLK4 INHIBITORS
EA202092001A1 (ru)	2018-03-27	2021-01-29	ПиТиСи ТЕРАПЬЮТИКС, ИНК.	Соединения для лечения болезни гентингтона
CN112367991A (zh)	2018-06-25	2021-02-12	达纳-法伯癌症研究所股份有限公司	Taire家族激酶抑制剂及其用途
CN112805280B (zh)	2018-06-27	2024-12-06	Ptc医疗公司	用于治疗亨廷顿氏病的杂芳基化合物
US11685746B2 (en)	2018-06-27	2023-06-27	Ptc Therapeutics, Inc.	Heteroaryl compounds for treating Huntington's disease
SG11202012674PA (en)	2018-06-27	2021-01-28	Ptc Therapeutics Inc	Heterocyclic and heteroaryl compounds for treating huntington's disease
CN115925705B (zh) *	2018-11-30	2024-12-31	江苏豪森药业集团有限公司	杂芳类衍生物调节剂、其制备方法和应用
WO2020140098A1 (en)	2018-12-28	2020-07-02	Dana-Farber Cancer Institute, Inc.	Inhibitors of cyclin-dependent kinase 7 and uses thereof
ES2994097T3 (en)	2019-04-24	2025-01-17	Theravance Biopharma R&D Ip Llc	Pyrimidine jak inhibitors for the treatment of skin diseases
CA3135383A1 (en)	2019-04-24	2020-10-29	Theravance Biopharma R&D Ip, Llc	Ester and carbonate pyrimidine compounds as jak kinase inhibitors
WO2021019514A1 (en)	2019-08-01	2021-02-04	Integral Biosciences Pvt. Ltd.	Heterocyclic compounds as kinase inhibitor and uses thereof
JP7695232B2 (ja)	2019-09-18	2025-06-18	武田薬品工業株式会社	ヘテロアリール血漿カリクレインインヒビター
JP2022548696A (ja)	2019-09-18	2022-11-21	武田薬品工業株式会社	血漿カリクレインインヒビター及びその使用
CN110483493A (zh) *	2019-09-19	2019-11-22	广东工业大学	一种二唑类衍生物及其制备方法和应用
US11844754B2 (en)	2020-11-17	2023-12-19	Neuroderm, Ltd.	Methods for treatment of Parkinson's disease
US11213502B1 (en)	2020-11-17	2022-01-04	Neuroderm, Ltd.	Method for treatment of parkinson's disease
US11331293B1 (en)	2020-11-17	2022-05-17	Neuroderm, Ltd.	Method for treatment of Parkinson's disease
TW202237119A (zh)	2020-12-10	2022-10-01	美商住友製藥腫瘤公司	Ａｌｋ﹘５抑制劑和彼之用途
CN117355523A (zh) *	2021-03-17	2024-01-05	武田药品工业株式会社	血浆激肽释放酶的多环抑制剂
CA3213359A1 (en) *	2021-03-26	2022-09-29	Bettina FRANZ	Alk-5 inhibitors and uses thereof
KR20240035390A (ko)	2021-05-11	2024-03-15	오릭 파마슈티칼스, 인크.	폴로 유사 키나제 4 억제제
CA3223223A1 (en)	2021-06-28	2023-01-05	Blueprint Medicines Corporation	Cdk2 inhibitors
KR102692529B1 (ko) *	2021-07-01	2024-08-08	한국원자력의학원	Mastl-pp2a를 표적화하는 암의 예방 또는 치료용 약학적 조성물
CN116354938B (zh) *	2021-12-28	2024-02-20	沈阳药科大学	一类喹唑啉衍生物与其类似物的制备方法及应用
CN114276302B (zh) *	2022-01-11	2023-07-25	山东百启生物医药有限公司	一种制备2,4-二氨基喹唑啉衍生物的方法
CN116813595B (zh) *	2022-03-28	2025-07-18	上海医药工业研究院有限公司	喹唑啉类衍生物、其制备方法、药物组合物及应用
WO2024003773A1 (en)	2022-07-01	2024-01-04	Pfizer Inc.	2,7-naphthyridine compounds as mastl inhibitors
CN115403568B (zh) *	2022-09-21	2023-09-29	中山大学	一种喹唑啉类Aurora A共价抑制剂及其制备方法和应用
CN117736198A (zh) *	2022-09-21	2024-03-22	科辉智药生物科技(深圳)有限公司	大环含氮冠醚化合物及其作为蛋白激酶抑制剂的应用
US20240317777A1 (en) *	2023-02-23	2024-09-26	Accutar Biotechnology Inc.	Novel macrocyclic aminopyrazole compounds as cdk2 inhibitors
US12161612B2 (en)	2023-04-14	2024-12-10	Neuroderm, Ltd.	Methods and compositions for reducing symptoms of Parkinson's disease

Family Cites Families (102)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US18436A (en) *		1857-10-20		And saml
US2585906A (en)		1952-02-12		Quaternary salts of pyrimdjines
US3133081A (en) *		1964-05-12		J-aminoindazole derivatives
US3935183A (en) *	1970-01-26	1976-01-27	Imperial Chemical Industries Limited	Indazole-azo phenyl compounds
BE754242A (fr) *	1970-07-15	1971-02-01	Geigy Ag J R	Diamino-s-triazines et dinitro-s-triazines
US3755332A (en) *	1971-07-01	1973-08-28	Ciba Geigy Corp	Substituted 4 indazolaminoquinolines
US3998951A (en) *	1974-03-13	1976-12-21	Fmc Corporation	Substituted 2-arylquinazolines as fungicides
DE2458965C3 (de) *	1974-12-13	1979-10-11	Bayer Ag, 5090 Leverkusen	3-Amino-indazol-N-carbonsäure-Derivate, Verfahren zu ihrer Herstellung sowie sie enthaltende Arzneimittel
MA18829A1 (fr)	1979-05-18	1980-12-31	Ciba Geigy Ag	Derives de la pyrimidine,procedes pour leur preparation,compositions pharmaceutiques contenant ces composes et leur utilisation therapeutique
DOP1981004033A (es) *	1980-12-23	1990-12-29	Ciba Geigy Ag	Procedimiento para proteger plantas de cultivo de la accion fitotoxica de herbicidas.
SE8102193L (sv) *	1981-04-06	1982-10-07	Pharmacia Ab	Terapeutiskt aktiv organisk forening och dess anvendning
SE8102194L (sv) *	1981-04-06	1982-10-07	Pharmacia Ab	Terapeutiskt aktiv organisk forening och farmaceutisk beredning innehallande denna
JPS58124773A (ja)	1982-01-20	1983-07-25	Mitsui Toatsu Chem Inc	５−メチルチオピリミジン誘導体とその製造法と農園芸用殺菌剤
EP0136976A3 (de)	1983-08-23	1985-05-15	Ciba-Geigy Ag	Verwendung von Phenylpyrimidinen als Pflanzenregulatoren
DE3725638A1 (de)	1987-08-03	1989-02-16	Bayer Ag	Neue aryloxy (bzw. thio)aminopyrimidine
JPH0532662A (ja)	1990-11-09	1993-02-09	Nissan Chem Ind Ltd	置換ピラゾール誘導体および農園芸用殺菌剤
US5714493A (en) *	1991-05-10	1998-02-03	Rhone-Poulenc Rorer Pharmaceuticals, Inc.	Aryl and heteroaryl quinazoline compounds which inhibit CSF-1R receptor tyrosine kinase
US5710158A (en) *	1991-05-10	1998-01-20	Rhone-Poulenc Rorer Pharmaceuticals Inc.	Aryl and heteroaryl quinazoline compounds which inhibit EGF and/or PDGF receptor tyrosine kinase
US5597920A (en)	1992-04-30	1997-01-28	Neurogen Corporation	Gabaa receptor subtypes and methods for screening drug compounds using imidazoquinoxalines and pyrrolopyrimidines to bind to gabaa receptor subtypes
JPH0665237A (ja) *	1992-05-07	1994-03-08	Nissan Chem Ind Ltd	置換ピラゾール誘導体および農園芸用殺菌剤
DE69434721T2 (de)	1993-10-01	2006-11-09	Novartis Ag	Pharmacologisch wirksame pyrimidinderivate und verfahren zu deren herstellung
AU700964B2 (en)	1994-11-10	1999-01-14	Cor Therapeutics, Inc.	Pharmaceutical pyrazole compositions useful as inhibitors of protein kinases
IL117659A (en) *	1995-04-13	2000-12-06	Dainippon Pharmaceutical Co	Substituted 2-phenyl pyrimidino amino acetamide derivative process for preparing the same and a pharmaceutical composition containing same
WO1997009325A1 (en)	1995-09-01	1997-03-13	Signal Pharmaceuticals, Inc.	Pyrimidine carboxylates and related compounds and methods for treating inflammatory conditions
US5935966A (en)	1995-09-01	1999-08-10	Signal Pharmaceuticals, Inc.	Pyrimidine carboxylates and related compounds and methods for treating inflammatory conditions
GB9523675D0 (en)	1995-11-20	1996-01-24	Celltech Therapeutics Ltd	Chemical compounds
US6716575B2 (en) *	1995-12-18	2004-04-06	Sugen, Inc.	Diagnosis and treatment of AUR1 and/or AUR2 related disorders
DE69716916T2 (de)	1996-07-13	2003-07-03	Glaxo Group Ltd., Greenford	Kondensierte heterozyklische verbindungen als protein kinase inhibitoren
JPH10130150A (ja)	1996-09-05	1998-05-19	Dainippon Pharmaceut Co Ltd	酢酸アミド誘導体からなる医薬
GB9619284D0 (en) *	1996-09-16	1996-10-30	Celltech Therapeutics Ltd	Chemical compounds
US6251911B1 (en)	1996-10-02	2001-06-26	Novartis Ag	Pyrimidine derivatives and processes for the preparation thereof
JP2001506974A (ja)	1996-10-11	2001-05-29	ワーナー―ランバート・コンパニー	インターロイキン―１β変換酵素のアスパルテートエステル阻害剤
DE19710435A1 (de) *	1997-03-13	1998-09-17	Hoechst Ag	Verwendung von Pyrimidinderivaten zur Prävention von Krebs allein oder in Kombination mit anderen therapeutischen Maßnahmen
WO1999018781A1 (en)	1997-10-10	1999-04-22	Cytovia, Inc.	Dipeptide apoptosis inhibitors and the use thereof
US6267952B1 (en) *	1998-01-09	2001-07-31	Geltex Pharmaceuticals, Inc.	Lipase inhibiting polymers
JP2000026421A (ja)	1998-01-29	2000-01-25	Kumiai Chem Ind Co Ltd	ジアリ―ルスルフィド誘導体及び有害生物防除剤
IL137922A0 (en)	1998-02-17	2001-10-31	Tularik Inc	Anti-viral pyrimidine derivatives
AU755273B2 (en)	1998-03-16	2002-12-05	Cytovia, Inc.	Dipeptide caspase inhibitors and the use thereof
MXPA00011889A (es)	1998-06-02	2003-04-25	Osi Pharm Inc	Composiciones de pirrolo (2,3d) piridina y su uso.
EP1087963B1 (en)	1998-06-19	2004-08-25	Chiron Corporation	Inhibitors of glycogen synthase kinase 3
WO2000003901A1 (de) *	1998-07-16	2000-01-27	Continental Teves Ag & Co. Ohg	Verfahren und vorrichtung zum ermitteln von kritischen fahrzuständen bei im fahrbetrieb befindlichen fahrzeugen
AU5777299A (en) *	1998-08-21	2000-03-14	Du Pont Pharmaceuticals Company	Isoxazolo(4,5-d)pyrimidines as CRF antagonists
US6184226B1 (en) *	1998-08-28	2001-02-06	Scios Inc.	Quinazoline derivatives as inhibitors of P-38 α
US7262201B1 (en) *	1998-10-08	2007-08-28	Astrazeneca Ab	Quinazoline derivatives
GB9828640D0 (en)	1998-12-23	1999-02-17	Smithkline Beecham Plc	Novel method and compounds
GB9828511D0 (en) *	1998-12-24	1999-02-17	Zeneca Ltd	Chemical compounds
GEP20032999B (en)	1999-01-13	2003-06-25	Warner Lambert Co	1-Heterocycle Substituted Diarylamines
GB9905075D0 (en) *	1999-03-06	1999-04-28	Zeneca Ltd	Chemical compounds
CA2366857C (en)	1999-03-30	2010-12-14	Novartis Ag	Phthalazine derivatives for treating inflammatory diseases
JP2003502424A (ja) *	1999-06-17	2003-01-21	シオノギバイオリサーチコーポレイション	Ｉｌ−１２産生の阻害物質
GB9914258D0 (en) *	1999-06-18	1999-08-18	Celltech Therapeutics Ltd	Chemical compounds
BR0013551A (pt)	1999-08-13	2003-06-17	Vertex Pharma	Inibidores de cinases n-terminal cjun (jnk) e outras cinases de proteìnas
ATE396978T1 (de)	1999-10-07	2008-06-15	Amgen Inc	Triazin-kinase-hemmer
IL149103A0 (en)	1999-11-30	2002-11-10	Pfizer Prod Inc	2,4-diaminopyrimidine compounds useful as immunosuppressants
EP1246623B1 (en)	1999-12-02	2006-08-09	OSI Pharmaceuticals, Inc.	Compounds specific to adenosine a1, a2a, and a3 receptor and uses thereof
US6376489B1 (en)	1999-12-23	2002-04-23	Icos Corporation	Cyclic AMP-specific phosphodiesterase inhibitors
MY125768A (en)	1999-12-15	2006-08-30	Bristol Myers Squibb Co	N-[5-[[[5-alkyl-2-oxazolyl]methyl]thio]-2-thiazolyl]-carboxamide inhibitors of cyclin dependent kinases
JP4794793B2 (ja)	1999-12-28	2011-10-19	ファーマコペイア，インコーポレイテッド	Ｎ−ヘテロ環ＴＮＦ−α発現阻害剤
US20020065270A1 (en)	1999-12-28	2002-05-30	Moriarty Kevin Joseph	N-heterocyclic inhibitors of TNF-alpha expression
KR20010111298A (ko) *	2000-02-05	2001-12-17	버텍스 파마슈티칼스 인코포레이티드	Ｅｒｋ의 억제제로서 유용한 피라졸 조성물
JP2003532635A (ja) *	2000-02-17	2003-11-05	アムジエン・インコーポレーテツド	キナーゼ阻害薬
GB0004887D0 (en) *	2000-03-01	2000-04-19	Astrazeneca Uk Ltd	Chemical compounds
GB0004890D0 (en) *	2000-03-01	2000-04-19	Astrazeneca Uk Ltd	Chemical compounds
PT1268519E (pt)	2000-04-03	2005-08-31	Vertex Pharma	Inibidores de serina protease, particularmente protease ns3 do virus da hepatite c
WO2001079198A1 (en)	2000-04-18	2001-10-25	Agouron Pharmaceuticals, Inc.	Pyrazoles for inhibiting protein kinase
JP3890184B2 (ja) *	2000-05-15	2007-03-07	Ｎｅｃパーソナルプロダクツ株式会社	電源装置及びその電力制御方法、情報処理機器
ES2305081T3 (es) *	2000-06-28	2008-11-01	Astrazeneca Ab	Derivados de quinozolina sustituidos y su uso como inhibidores.
CN102206247B (zh)	2000-07-21	2013-03-27	默沙东公司	一种具有HCV NS3/NS4a蛋白酶抑制活性的化合物
EA200300205A1 (ru)	2000-08-31	2003-06-26	Пфайзер Продактс Инк.	Производные пиразола и их применение в качестве ингибиторов протеинкиназы
NZ525016A (en) *	2000-09-15	2004-10-29	Vertex Pharma	Isoxazoles and their use as inhibitors of ERK
US6613776B2 (en) *	2000-09-15	2003-09-02	Vertex Pharmaceuticals Incorporated	Pyrazole compounds useful as protein kinase inhibitors
US7473691B2 (en) *	2000-09-15	2009-01-06	Vertex Pharmaceuticals Incorporated	Pyrazole compounds useful as protein kinase inhibitors
US6660731B2 (en) *	2000-09-15	2003-12-09	Vertex Pharmaceuticals Incorporated	Pyrazole compounds useful as protein kinase inhibitors
WO2002022608A1 (en)	2000-09-15	2002-03-21	Vertex Pharmaceuticals Incorporated	Pyrazole compounds useful as protein kinase inhibitors
US6610677B2 (en) *	2000-09-15	2003-08-26	Vertex Pharmaceuticals Incorporated	Pyrazole compounds useful as protein kinase inhibitors
JP2004509876A (ja)	2000-09-20	2004-04-02	メルク　パテント　ゲゼルシャフト　ミット　ベシュレンクテル　ハフトング	４−アミノ−キナゾリン
US6641579B1 (en)	2000-09-29	2003-11-04	Spectrasonics Imaging, Inc.	Apparatus and method for ablating cardiac tissue
US6716851B2 (en) *	2000-12-12	2004-04-06	Cytovia, Inc.	Substituted 2-aryl-4-arylaminopyrimidines and analogs as activators or caspases and inducers of apoptosis and the use thereof
DE10061863A1 (de) *	2000-12-12	2002-06-13	Basf Ag	Verfahren zur Herstellung von Triethylendiamin (TEDA)
AU2002228922A1 (en)	2000-12-12	2002-06-24	Cytovia, Inc.	Substituted 2-aryl-4-arylaminopyrimidines and analogs as activators of caspases and inducers of apoptosis and the use thereof
ATE327989T1 (de)	2000-12-21	2006-06-15	Vertex Pharma	Pyrazolverbindungen als protein-kinase- inhibitoren
MY130778A (en) *	2001-02-09	2007-07-31	Vertex Pharma	Heterocyclic inhibitiors of erk2 and uses thereof
DE60223790T4 (de)	2001-03-29	2009-05-07	Vertex Pharmaceuticals Inc., Cambridge	Hemmer von c-jun-terminal kinase (jnk) und andere protein kinase
WO2002083667A2 (en) *	2001-04-13	2002-10-24	Vertex Pharmaceuticals Incorporated	Inhibitors of c-jun n-terminal kinases (jnk) and other protein kinases
WO2002085909A1 (en) *	2001-04-20	2002-10-31	Vertex Pharmaceuticals Incorporated	9-deazaguanine derivatives as inhibitors of gsk-3
EP1404669A2 (en) *	2001-05-16	2004-04-07	Vertex Pharmaceuticals Incorporated	Heterocyclic substituted pyrazoles as inhibitors of src and other protein kinases
EP1399440B1 (en) *	2001-06-15	2009-06-03	Vertex Pharmaceuticals Incorporated	5-(2-aminopyrimidin-4-yl)benzisoxazoles as protein kinase inhibitors
ES2271283T3 (es) *	2001-07-03	2007-04-16	Vertex Pharmaceuticals Incorporated	Isoxazolil-pirimidinas como inhibidores de las proteinas quinasas src y lck.
WO2003026666A1 (en) *	2001-09-26	2003-04-03	Bayer Pharmaceuticals Corporation	2-phenylamino-4- (5-pyrazolylamino)-pyrimidine derivatives as kinase inhibitors, in particular, as src kinase inhibitors
US6569499B2 (en)	2001-10-02	2003-05-27	Xerox Corporation	Apparatus and method for coating photoreceptor substrates
EP2198867A1 (en) *	2001-12-07	2010-06-23	Vertex Pharmaceuticals, Inc.	Pyrimidine-based compounds useful as GSK-3 inhibitors
WO2003078427A1 (en) *	2002-03-15	2003-09-25	Vertex Pharmaceuticals, Inc.	Azolylaminoazines as inhibitors of protein kinases
EP1485376B1 (en) *	2002-03-15	2007-06-27	Vertex Pharmaceuticals Incorporated	Compositions useful as inhibitors of protein kinases
AU2003220299A1 (en) *	2002-03-15	2003-09-29	Vertex Pharmaceuticals, Inc.	Azinylaminoazoles as inhibitors of protein kinases
WO2003078426A1 (en) *	2002-03-15	2003-09-25	Vertex Pharmaceuticals, Inc.	Azolylaminoazine as inhibitors of protein kinases
US20030207873A1 (en) *	2002-04-10	2003-11-06	Edmund Harrington	Inhibitors of Src and other protein kinases
WO2003091246A1 (en) *	2002-04-26	2003-11-06	Vertex Pharmaceuticals Incorporated	Pyrrole derivatives as inhibitors of erk2 and uses thereof
MY141867A (en) *	2002-06-20	2010-07-16	Vertex Pharma	Substituted pyrimidines useful as protein kinase inhibitors
EP1554269A1 (en) *	2002-07-09	2005-07-20	Vertex Pharmaceuticals Incorporated	Imidazoles, oxazoles and thiazoles with protein kinase inhibiting activities
EA200500299A1 (ru)	2002-08-02	2005-08-25	Вертекс Фармасьютикалз Инкорпорейтед	Пиразольные композиции, используемые в качестве ингибиторов gsk-3
AU2006297120B2 (en)	2005-09-30	2011-05-19	Miikana Therapeutics, Inc.	Substituted pyrazole compounds
DE602007007985D1 (de)	2006-12-19	2010-09-02	Vertex Pharma	Als inhibitoren von proteinkinasen geeignete aminopyrimidine

2001
- 2001-12-19 AT AT01271061T patent/ATE327989T1/de active
- 2001-12-19 JP JP2002567928A patent/JP4234435B2/ja not_active Expired - Fee Related
- 2001-12-19 KR KR1020037008385A patent/KR100889246B1/ko not_active Expired - Fee Related
- 2001-12-19 PL PL363246A patent/PL210066B1/pl unknown
- 2001-12-19 AT AT01994323T patent/ATE340172T1/de active
- 2001-12-19 MX MXPA03005610A patent/MXPA03005610A/es active IP Right Grant
- 2001-12-19 CA CA002432131A patent/CA2432131C/en not_active Expired - Fee Related
- 2001-12-19 DK DK01994323T patent/DK1353916T3/da active
- 2001-12-19 HU HU0400908A patent/HUP0400908A3/hu unknown
- 2001-12-19 KR KR1020037008387A patent/KR100843114B1/ko not_active Expired - Fee Related
- 2001-12-19 RU RU2003122209/04A patent/RU2355688C2/ru not_active IP Right Cessation
- 2001-12-19 US US10/026,967 patent/US6989385B2/en not_active Expired - Fee Related
- 2001-12-19 ES ES01994323T patent/ES2272567T3/es not_active Expired - Lifetime
- 2001-12-19 WO PCT/US2001/049140 patent/WO2002050065A2/en active IP Right Grant
- 2001-12-19 AU AU2001297619A patent/AU2001297619B2/en not_active Ceased
- 2001-12-19 BR BR0116493-7A patent/BR0116493A/pt not_active IP Right Cessation
- 2001-12-19 NZ NZ526472A patent/NZ526472A/en not_active IP Right Cessation
- 2001-12-19 EP EP06011799A patent/EP1702920B1/en not_active Expired - Lifetime
- 2001-12-19 JP JP2002559413A patent/JP4160392B2/ja not_active Expired - Fee Related
- 2001-12-19 ES ES01985059T patent/ES2265446T3/es not_active Expired - Lifetime
- 2001-12-19 WO PCT/US2001/051120 patent/WO2002059111A2/en active IP Right Grant
- 2001-12-19 ES ES06011799T patent/ES2375491T3/es not_active Expired - Lifetime
- 2001-12-19 KR KR1020037008409A patent/KR100909665B1/ko not_active Expired - Fee Related
- 2001-12-19 AU AU2002234047A patent/AU2002234047A1/en not_active Abandoned
- 2001-12-19 SI SI200130656T patent/SI1353916T1/sl unknown
- 2001-12-19 EP EP01271061A patent/EP1345922B1/en not_active Expired - Lifetime
- 2001-12-19 JP JP2002557938A patent/JP4210520B2/ja not_active Expired - Fee Related
- 2001-12-19 DE DE60119776T patent/DE60119776T2/de not_active Expired - Lifetime
- 2001-12-19 NZ NZ526468A patent/NZ526468A/en not_active IP Right Cessation
- 2001-12-19 PL PL363244A patent/PL210414B1/pl not_active IP Right Cessation
- 2001-12-19 KR KR10-2003-7008415A patent/KR20030061858A/ko not_active Abandoned
- 2001-12-19 EP EP01993360A patent/EP1345926B1/en not_active Expired - Lifetime
- 2001-12-19 EP EP01994323A patent/EP1353916B1/en not_active Expired - Lifetime
- 2001-12-19 EP EP01273861A patent/EP1355905B1/en not_active Expired - Lifetime
- 2001-12-19 KR KR1020037008397A patent/KR100947185B1/ko not_active Expired - Fee Related
- 2001-12-19 KR KR1020037008427A patent/KR100875091B1/ko not_active Expired - Fee Related
- 2001-12-19 AP APAP/P/2003/002816A patent/AP1588A/en active
- 2001-12-19 NZ NZ526469A patent/NZ526469A/en not_active IP Right Cessation
- 2001-12-19 WO PCT/US2001/049139 patent/WO2002066461A1/en active IP Right Grant
- 2001-12-19 AU AU2002255452A patent/AU2002255452B2/en not_active Ceased
- 2001-12-19 US US10/025,164 patent/US6664247B2/en not_active Expired - Fee Related
- 2001-12-19 CN CNA018221033A patent/CN1486310A/zh active Pending
- 2001-12-19 AT AT06011799T patent/ATE528303T1/de not_active IP Right Cessation
- 2001-12-19 US US10/026,992 patent/US7625913B2/en not_active Expired - Fee Related
- 2001-12-19 SI SI200130722T patent/SI1355905T1/sl unknown
- 2001-12-19 WO PCT/US2001/051031 patent/WO2002062789A1/en active IP Right Grant
- 2001-12-19 EP EP10184271A patent/EP2264028A1/en not_active Withdrawn
- 2001-12-19 ES ES01994510T patent/ES2265452T3/es not_active Expired - Lifetime
- 2001-12-19 NZ NZ526471A patent/NZ526471A/en not_active IP Right Cessation
- 2001-12-19 US US10/026,975 patent/US6653300B2/en not_active Expired - Fee Related
- 2001-12-19 IL IL15636801A patent/IL156368A0/xx not_active IP Right Cessation
- 2001-12-19 PT PT01271061T patent/PT1345922E/pt unknown
- 2001-12-19 NZ NZ526473A patent/NZ526473A/en not_active IP Right Cessation
- 2001-12-19 ES ES01993360T patent/ES2265450T3/es not_active Expired - Lifetime
- 2001-12-19 MX MXPA03005608A patent/MXPA03005608A/es not_active Application Discontinuation
- 2001-12-19 JP JP2002563142A patent/JP4160395B2/ja not_active Expired - Fee Related
- 2001-12-19 AT AT01993360T patent/ATE326461T1/de active
- 2001-12-19 CA CA002432799A patent/CA2432799C/en not_active Expired - Fee Related
- 2001-12-19 MX MXPA03005609A patent/MXPA03005609A/es active IP Right Grant
- 2001-12-19 WO PCT/US2001/050312 patent/WO2002068415A1/en active IP Right Grant
- 2001-12-19 CA CA002432222A patent/CA2432222C/en not_active Expired - Fee Related
- 2001-12-19 US US10/026,966 patent/US20030105090A1/en not_active Abandoned
- 2001-12-19 DK DK01273861T patent/DK1355905T3/da active
- 2001-12-19 ES ES01271061T patent/ES2266095T3/es not_active Expired - Lifetime
- 2001-12-19 DE DE60120219T patent/DE60120219T2/de not_active Expired - Lifetime
- 2001-12-19 IL IL15640801A patent/IL156408A0/xx unknown
- 2001-12-19 CN CN2011101042845A patent/CN102250071A/zh active Pending
- 2001-12-19 IL IL15636901A patent/IL156369A0/xx active IP Right Grant
- 2001-12-19 MX MXPA03005605A patent/MXPA03005605A/es active IP Right Grant
- 2001-12-19 WO PCT/US2001/049401 patent/WO2002057259A2/en active Application Filing
- 2001-12-19 AT AT01985059T patent/ATE326460T1/de active
- 2001-12-19 IL IL15640701A patent/IL156407A0/xx not_active IP Right Cessation
- 2001-12-19 CN CNB01822105XA patent/CN100406454C/zh not_active Expired - Fee Related
- 2001-12-19 HU HU0400638A patent/HUP0400638A2/hu unknown
- 2001-12-19 HU HU0400639A patent/HUP0400639A3/hu unknown
- 2001-12-19 AP APAP/P/2003/002825A patent/AP2003002825A0/en unknown
- 2001-12-19 CA CA2432303A patent/CA2432303C/en not_active Expired - Fee Related
- 2001-12-19 CN CNB018221351A patent/CN100408573C/zh not_active Expired - Fee Related
- 2001-12-19 PT PT01273861T patent/PT1355905E/pt unknown
- 2001-12-19 CN CNB018221025A patent/CN100436452C/zh not_active Expired - Fee Related
- 2001-12-19 CN CNB01822136XA patent/CN100340555C/zh not_active Expired - Fee Related
- 2001-12-19 HU HU0400842A patent/HUP0400842A2/hu unknown
- 2001-12-19 DE DE60126828T patent/DE60126828T2/de not_active Expired - Lifetime
- 2001-12-19 MX MXPA03005607A patent/MXPA03005607A/es active IP Right Grant
- 2001-12-19 JP JP2002565976A patent/JP2004518743A/ja active Pending
- 2001-12-19 DE DE60123283T patent/DE60123283T2/de not_active Expired - Lifetime
- 2001-12-19 EP EP01994510A patent/EP1345927B1/en not_active Expired - Lifetime
- 2001-12-19 AT AT01273861T patent/ATE354573T1/de active
- 2001-12-19 EP EP01985059A patent/EP1345925B1/en not_active Expired - Lifetime
- 2001-12-19 JP JP2002551561A patent/JP4160389B2/ja not_active Expired - Fee Related
- 2001-12-19 MX MXPA03005606A patent/MXPA03005606A/es active IP Right Grant
- 2001-12-19 AT AT01994510T patent/ATE326462T1/de active
- 2001-12-19 ES ES01273861T patent/ES2280313T3/es not_active Expired - Lifetime
- 2001-12-19 DE DE60119774T patent/DE60119774T2/de not_active Expired - Lifetime
- 2001-12-19 CA CA002432129A patent/CA2432129C/en not_active Expired - Fee Related
- 2001-12-19 DE DE60119775T patent/DE60119775T2/de not_active Expired - Lifetime
- 2001-12-19 NZ NZ526470A patent/NZ526470A/xx not_active IP Right Cessation
- 2001-12-19 PT PT01994323T patent/PT1353916E/pt unknown
- 2001-12-19 HU HU0400641A patent/HUP0400641A3/hu unknown
- 2001-12-19 IL IL15638901A patent/IL156389A0/xx active IP Right Grant
- 2001-12-19 DK DK01271061T patent/DK1345922T3/da active
- 2001-12-19 CA CA002432223A patent/CA2432223C/en not_active Expired - Fee Related
- 2001-12-19 BR BR0116411-2A patent/BR0116411A/pt not_active IP Right Cessation
- 2001-12-19 US US10/027,001 patent/US6653301B2/en not_active Expired - Fee Related
- 2001-12-20 DE DE60119777T patent/DE60119777T2/de not_active Expired - Lifetime
- 2001-12-20 AU AU3116602A patent/AU3116602A/xx active Pending
- 2001-12-20 AT AT01994347T patent/ATE326463T1/de not_active IP Right Cessation
- 2001-12-20 EP EP01991439A patent/EP1345928B1/en not_active Expired - Lifetime
- 2001-12-20 WO PCT/US2001/049585 patent/WO2002050066A2/en active IP Right Grant
- 2001-12-20 AR ARP010105963A patent/AR040925A1/es active IP Right Grant
- 2001-12-20 MX MXPA03005611A patent/MXPA03005611A/es unknown
- 2001-12-20 US US10/034,019 patent/US6727251B2/en not_active Expired - Fee Related
- 2001-12-20 MX MXPA03005612A patent/MXPA03005612A/es not_active Application Discontinuation
- 2001-12-20 KR KR10-2003-7008364A patent/KR20030061463A/ko not_active Abandoned
- 2001-12-20 AU AU2002231166A patent/AU2002231166B2/en not_active Ceased
- 2001-12-20 WO PCT/US2001/049594 patent/WO2002059112A2/en active IP Right Grant
- 2001-12-20 AR ARP010105960A patent/AR042397A1/es active IP Right Grant
- 2001-12-20 KR KR10-2003-7008366A patent/KR20030061464A/ko not_active Withdrawn
- 2001-12-20 DE DE60126658T patent/DE60126658T2/de not_active Expired - Lifetime
- 2001-12-20 CA CA002432872A patent/CA2432872C/en not_active Expired - Fee Related
- 2001-12-20 CA CA002432132A patent/CA2432132C/en not_active Expired - Fee Related
- 2001-12-20 AR ARP010105961A patent/AR042398A1/es unknown
- 2001-12-20 JP JP2002551562A patent/JP2004516292A/ja active Pending
- 2001-12-20 EP EP01994347A patent/EP1345929B1/en not_active Expired - Lifetime
- 2001-12-20 AR ARP010105962A patent/AR042169A1/es active IP Right Grant
- 2001-12-20 NZ NZ526474A patent/NZ526474A/en unknown
- 2001-12-20 AU AU2002246754A patent/AU2002246754B2/en not_active Ceased
- 2001-12-20 NZ NZ526475A patent/NZ526475A/en unknown
- 2001-12-20 AT AT01991439T patent/ATE353890T1/de not_active IP Right Cessation
- 2001-12-20 US US10/034,683 patent/US6656939B2/en not_active Expired - Fee Related
- 2001-12-20 JP JP2002559414A patent/JP2004517927A/ja active Pending
- 2001-12-21 MY MYPI20015823A patent/MY140377A/en unknown
- 2001-12-25 TW TW090131846A patent/TWI290551B/zh not_active IP Right Cessation
- 2001-12-25 TW TW095139649A patent/TWI313269B/zh not_active IP Right Cessation
2003
- 2003-06-10 IL IL156369A patent/IL156369A/en not_active IP Right Cessation
- 2003-06-11 IL IL156389A patent/IL156389A/en not_active IP Right Cessation
- 2003-06-12 NO NO20032671A patent/NO20032671L/no not_active Application Discontinuation
- 2003-06-12 NO NO20032670A patent/NO328537B1/no not_active IP Right Cessation
- 2003-06-13 NO NO20032704A patent/NO330527B1/no not_active IP Right Cessation
- 2003-06-13 NO NO20032703A patent/NO328501B1/no not_active IP Right Cessation
- 2003-06-16 NO NO20032736A patent/NO20032736L/no unknown
- 2003-08-01 US US10/632,428 patent/US7531536B2/en not_active Expired - Fee Related
- 2003-11-25 US US10/722,374 patent/US20040157893A1/en not_active Abandoned
- 2003-12-15 US US10/736,426 patent/US7087603B2/en not_active Expired - Fee Related
2004
- 2004-02-10 US US10/775,699 patent/US7427681B2/en not_active Expired - Fee Related
- 2004-12-17 JP JP2004366925A patent/JP2005097322A/ja not_active Withdrawn
2006
- 2006-03-21 AU AU2006201267A patent/AU2006201267B2/en not_active Ceased
- 2006-12-20 CY CY20061101823T patent/CY1106297T1/el unknown
2008
- 2008-04-01 JP JP2008095581A patent/JP2008189682A/ja not_active Withdrawn
- 2008-04-01 JP JP2008095584A patent/JP2008260767A/ja not_active Withdrawn
- 2008-04-03 JP JP2008097620A patent/JP2008222719A/ja active Pending
- 2008-04-04 JP JP2008098506A patent/JP2008189687A/ja active Pending
- 2008-04-25 US US12/109,598 patent/US8304414B2/en not_active Expired - Fee Related
- 2008-05-07 JP JP2008121727A patent/JP2008247921A/ja active Pending
- 2008-05-07 JP JP2008121724A patent/JP2008247920A/ja active Pending
- 2008-05-07 JP JP2008121723A patent/JP2008201808A/ja active Pending
2009
- 2009-04-17 JP JP2009101481A patent/JP5249842B2/ja not_active Expired - Fee Related
- 2009-08-21 US US12/545,347 patent/US7982037B2/en not_active Expired - Fee Related
- 2009-09-14 JP JP2009212566A patent/JP2009286805A/ja not_active Withdrawn
2010
- 2010-12-07 IL IL209827A patent/IL209827A0/en unknown
2012
- 2012-09-28 US US13/631,488 patent/US8697698B2/en not_active Expired - Fee Related
2013
- 2013-07-19 JP JP2013150948A patent/JP2013213068A/ja active Pending
- 2013-12-24 US US14/139,889 patent/US20140187772A1/en not_active Abandoned

Also Published As

Publication number	Publication date
AU2002231166B2 (en)	2008-02-21
DE60119777T2 (de)	2007-05-03
NO20032670D0 (no)	2003-06-12
NO20032736D0 (no)	2003-06-16
US20030036543A1 (en)	2003-02-20
NO20032704D0 (no)	2003-06-13
CN100406454C (zh)	2008-07-30
NO20032670L (no)	2003-08-15
KR100889246B1 (ko)	2009-03-19
EP1345929A2 (en)	2003-09-24
US20040167141A1 (en)	2004-08-26
KR100909665B1 (ko)	2009-07-29
JP2013213068A (ja)	2013-10-17
CN1486310A (zh)	2004-03-31
EP1355905A1 (en)	2003-10-29
EP1355905B1 (en)	2007-02-21
HUP0400908A3 (en)	2010-03-29
CA2432132A1 (en)	2002-08-01
JP4160389B2 (ja)	2008-10-01
MXPA03005608A (es)	2003-10-06
TWI290551B (en)	2007-12-01
JP4160395B2 (ja)	2008-10-01
ES2266095T3 (es)	2007-03-01
US7087603B2 (en)	2006-08-08
EP1345928A2 (en)	2003-09-24
KR20030061857A (ko)	2003-07-22
NZ526468A (en)	2004-03-26
IL156369A0 (en)	2004-01-04
KR20030061467A (ko)	2003-07-18
NO20032671D0 (no)	2003-06-12
DE60119775D1 (de)	2006-06-22
JP2004517894A (ja)	2004-06-17
US6653300B2 (en)	2003-11-25
PT1345922E (pt)	2006-09-29
DE60126828D1 (de)	2007-04-05
HUP0400842A2 (hu)	2004-07-28
US6989385B2 (en)	2006-01-24
NZ526472A (en)	2004-04-30
MXPA03005605A (es)	2003-10-06
US20040157893A1 (en)	2004-08-12
HUP0400908A2 (hu)	2004-07-28
US6653301B2 (en)	2003-11-25
RU2355688C2 (ru)	2009-05-20
DE60123283D1 (de)	2006-11-02
ES2265446T3 (es)	2007-02-16
US20080287444A1 (en)	2008-11-20
US20090312543A1 (en)	2009-12-17
WO2002057259A3 (en)	2003-04-24
AR040925A1 (es)	2005-04-27
DE60126658D1 (de)	2007-03-29
PL210414B1 (pl)	2012-01-31
ES2375491T3 (es)	2012-03-01
JP2008189687A (ja)	2008-08-21
NZ526473A (en)	2005-06-24
HK1061389A1 (en)	2004-09-17
JP2004517927A (ja)	2004-06-17
WO2002050066A3 (en)	2003-01-23
US20040132781A1 (en)	2004-07-08
WO2002059112A2 (en)	2002-08-01
JP5249842B2 (ja)	2013-07-31
ATE528303T1 (de)	2011-10-15
NO20032703D0 (no)	2003-06-13
HK1060557A1 (en)	2004-08-13
IL156369A (en)	2011-02-28
KR20030061463A (ko)	2003-07-18
CA2432131A1 (en)	2002-08-01
DE60119776D1 (de)	2006-06-22
CN102250071A (zh)	2011-11-23
US20030055068A1 (en)	2003-03-20
MXPA03005609A (es)	2003-10-06
US6664247B2 (en)	2003-12-16
IL156389A0 (en)	2004-01-04
KR20030061466A (ko)	2003-07-18
NZ526469A (en)	2005-10-28
ES2280313T3 (es)	2007-09-16
EP1353916A2 (en)	2003-10-22
WO2002057259A2 (en)	2002-07-25
HK1060349A1 (en)	2004-08-06
EP1702920B1 (en)	2011-10-12
NZ526471A (en)	2005-08-26
DE60119775T2 (de)	2007-05-10
JP2004519479A (ja)	2004-07-02
CA2432303C (en)	2010-04-13
JP2004516291A (ja)	2004-06-03
CA2432799C (en)	2008-08-19
IL156368A0 (en)	2004-01-04
US20050038023A1 (en)	2005-02-17
AU2006201267B2 (en)	2010-07-29
CA2432129C (en)	2008-08-26
JP2004518743A (ja)	2004-06-24
US20030078275A1 (en)	2003-04-24
CN1486312A (zh)	2004-03-31
BR0116411A (pt)	2003-11-11
EP1345922B1 (en)	2006-05-31
DK1353916T3 (da)	2007-01-29
AU3116602A (en)	2002-07-01
NO20032704L (no)	2003-08-21
AU2001297619B2 (en)	2006-06-08
EP1353916B1 (en)	2006-09-20
CA2432129A1 (en)	2002-07-25
MXPA03005607A (es)	2003-10-06
WO2002066461A1 (en)	2002-08-29
JP2008247920A (ja)	2008-10-16
ATE326461T1 (de)	2006-06-15
JP2009155352A (ja)	2009-07-16
KR20030061468A (ko)	2003-07-18
TWI313269B (en)	2009-08-11
JP2008201808A (ja)	2008-09-04
AU2002234047A1 (en)	2002-07-01
EP1345926A2 (en)	2003-09-24
EP1345928B1 (en)	2007-02-14
HK1062565A1 (zh)	2004-11-12
ES2265450T3 (es)	2007-02-16
JP2004518703A (ja)	2004-06-24
CA2432222A1 (en)	2002-08-15
WO2002059111A3 (en)	2003-01-09
CN100436452C (zh)	2008-11-26
AP1588A (en)	2006-03-06
JP4210520B2 (ja)	2009-01-21
NO330527B1 (no)	2011-05-09
DE60126828T2 (de)	2007-11-08
ATE326460T1 (de)	2006-06-15
AU2002255452B2 (en)	2006-06-08
HK1062433A1 (en)	2004-11-05
BR0116493A (pt)	2003-09-30
EP1702920A1 (en)	2006-09-20
DE60119774D1 (de)	2006-06-22
US7427681B2 (en)	2008-09-23
MY140377A (en)	2009-12-31
NZ526475A (en)	2005-06-24
US6656939B2 (en)	2003-12-02
HUP0400639A2 (hu)	2004-06-28
DE60119777D1 (de)	2006-06-22
JP2008247921A (ja)	2008-10-16
US8697698B2 (en)	2014-04-15
DE60120219T2 (de)	2007-04-12
CN100408573C (zh)	2008-08-06
JP4160392B2 (ja)	2008-10-01
PT1355905E (pt)	2007-05-31
KR100843114B1 (ko)	2008-07-02
CA2432223C (en)	2008-05-20
JP2008260767A (ja)	2008-10-30
CA2432132C (en)	2008-07-29
SI1355905T1 (sl)	2007-08-31
DK1345922T3 (da)	2006-09-18
EP1345927B1 (en)	2006-05-17
AR042398A1 (es)	2005-06-22
NO20032671L (no)	2003-08-18
EP1345927A1 (en)	2003-09-24
PL363246A1 (en)	2004-11-15
EP1345925A2 (en)	2003-09-24
US8304414B2 (en)	2012-11-06
CA2432222C (en)	2008-07-29
US7625913B2 (en)	2009-12-01
US20040214814A1 (en)	2004-10-28
CN1486311A (zh)	2004-03-31
US20030004164A1 (en)	2003-01-02
HUP0400638A2 (hu)	2004-06-28
DK1355905T3 (da)	2007-06-18
AR042397A1 (es)	2005-06-22
AU2002246754B2 (en)	2006-06-08
RU2003122209A (ru)	2005-02-10
HUP0400641A2 (hu)	2004-06-28
ATE326463T1 (de)	2006-06-15
ES2265452T3 (es)	2007-02-16
WO2002050066A2 (en)	2002-06-27
WO2002050065A2 (en)	2002-06-27
DE60120219D1 (de)	2006-07-06
US20030022885A1 (en)	2003-01-30
JP2009286805A (ja)	2009-12-10
WO2002059112A3 (en)	2003-02-06
IL156407A0 (en)	2004-01-04
US20030004161A1 (en)	2003-01-02
AP2003002816A0 (en)	2003-06-30
CA2432872C (en)	2008-09-23
WO2002062789A1 (en)	2002-08-15
MXPA03005610A (es)	2003-10-06
ATE354573T1 (de)	2007-03-15
EP1345925B1 (en)	2006-05-17
DE60119774T2 (de)	2007-05-16
MXPA03005606A (es)	2003-10-06
JP2004516292A (ja)	2004-06-03
US20030105090A1 (en)	2003-06-05
JP2004517926A (ja)	2004-06-17
HK1060346A1 (en)	2004-08-06
NZ526470A (en)	2006-03-31
US20140187772A1 (en)	2014-07-03
KR20030061858A (ko)	2003-07-22
ATE327989T1 (de)	2006-06-15
WO2002050065A3 (en)	2002-10-24
CN1487933A (zh)	2004-04-07
WO2002059111A2 (en)	2002-08-01
EP2264028A1 (en)	2010-12-22
AU2006201267A1 (en)	2006-04-27
HUP0400639A3 (en)	2010-03-29
US6727251B2 (en)	2004-04-27
KR100875091B1 (ko)	2008-12-22
DE60123283T2 (de)	2007-04-12
DE60119776T2 (de)	2007-05-16
WO2002068415A1 (en)	2002-09-06
CN1549812A (zh)	2004-11-24
MXPA03005611A (es)	2003-10-06
US20130096128A1 (en)	2013-04-18
ATE340172T1 (de)	2006-10-15
JP2008189682A (ja)	2008-08-21
JP4234435B2 (ja)	2009-03-04
CA2432799A1 (en)	2002-06-27
HK1060347A1 (en)	2004-08-06
JP2008222719A (ja)	2008-09-25
US7531536B2 (en)	2009-05-12
ATE353890T1 (de)	2007-03-15
DE60126658T2 (de)	2007-11-22
ES2272567T3 (es)	2007-05-01
IL209827A0 (en)	2011-02-28
KR100947185B1 (ko)	2010-03-15
NO20032736L (no)	2003-08-18
SI1353916T1 (sl)	2007-02-28
PL363244A1 (en)	2004-11-15
CA2432303A1 (en)	2002-08-29
PL210066B1 (pl)	2011-11-30
EP1345922A1 (en)	2003-09-24
NO328537B1 (no)	2010-03-15
EP1345929B1 (en)	2006-05-17
IL156408A0 (en)	2004-01-04
AP2003002825A0 (en)	2003-09-30
NZ526474A (en)	2005-10-28
EP1345926B1 (en)	2006-05-17
HUP0400641A3 (en)	2010-03-29
NO328501B1 (no)	2010-03-01
KR20030061465A (ko)	2003-07-18
NO20032703L (no)	2003-08-19
PT1353916E (pt)	2007-01-31
CA2432872A1 (en)	2002-06-27
CN100340555C (zh)	2007-10-03
US7982037B2 (en)	2011-07-19
CY1106297T1 (el)	2011-10-12
CA2432223A1 (en)	2002-09-06
ATE326462T1 (de)	2006-06-15
AR042169A1 (es)	2005-06-15
KR20030061464A (ko)	2003-07-18
JP2005097322A (ja)	2005-04-14
IL156389A (en)	2011-01-31
HK1059776A1 (en)	2004-07-16
CA2432131C (en)	2008-07-08
TW200716617A (en)	2007-05-01

Publication	Publication Date	Title
MXPA03002289A (es)	2003-06-06	Compuestos de pirazol utiles como inhibidores de proteina cinasa.
MXPA03005610A (es)	2003-10-06	Compuestos de pirazol utiles como inhibidores de la proteina cinasa.
AU2002231166A1 (en)	2002-09-05	Pyrazole compounds useful as protein kinase inhibitors
MXPA03004037A (es)	2003-08-19	Derivados de indolilmaleimida como inhibidores de proteina de cinasa c.
AU2001249865A1 (en)	2001-10-30	Pyrazoles for inhibiting protein kinase
MXPA03009847A (es)	2004-02-12	Inhibidores de cinasa derivados de pirazol.
ZA200206386B (en)	2003-11-26	Kinase inhibitors.
SI1318997T1 (sl)	2006-12-31	Pirazolne spojine, uporabne kot inhibitorji protein-kinaze
SI1345922T1 (sl)	2006-12-31	Pirazolne spojine, koristne kot inhibitorji protein kinaze
ZA200301704B (en)	2004-03-01	Triazole compounds useful as protein kinase inhibitors.
AU2006201396C1 (en)	2009-02-12	Pyrazole Compounds Useful As Protein Kinase Inhibitors
HK1051540A (en)	2003-08-08	Pyrazoles for inhibiting protein kinases
DK1317448T4 (da)	2011-05-30	Pyrazolforbindelser anvendelige som proteinkinaseinhibitorer

Legal Events

Date	Code	Title	Description
2016-08-31	FA	Abandonment or withdrawal